{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/worldhello23/nn/blob/main/f_rag_voyager.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "9e619-_lztXX"
      },
      "outputs": [],
      "source": [
        "from google.colab import userdata\n",
        "pine = userdata.get('pinecone_api')\n",
        "tog = userdata.get('together')\n",
        "voy = userdata.get('voyager')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "D2NKN3JRHCYX",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "0da7068a-c268-46a9-c69d-fd11636e561e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Writing to /root/.config/pip/pip.conf\n",
            "Collecting llama-index-embeddings-together\n",
            "  Downloading llama_index_embeddings_together-0.1.3-py3-none-any.whl (2.9 kB)\n",
            "Requirement already satisfied: llama-index-core<0.11.0,>=0.10.1 in /usr/local/lib/python3.10/dist-packages (from llama-index-embeddings-together) (0.10.37.post1)\n",
            "Requirement already satisfied: PyYAML>=6.0.1 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (6.0.1)\n",
            "Requirement already satisfied: SQLAlchemy[asyncio]>=1.4.49 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.0.30)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.6 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.9.5)\n",
            "Requirement already satisfied: dataclasses-json in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.6.6)\n",
            "Requirement already satisfied: deprecated>=1.2.9.3 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.2.14)\n",
            "Requirement already satisfied: dirtyjson<2.0.0,>=1.0.8 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.0.8)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2023.6.0)\n",
            "Requirement already satisfied: httpx in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.27.0)\n",
            "Requirement already satisfied: jsonpath-ng<2.0.0,>=1.6.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.6.1)\n",
            "Requirement already satisfied: llamaindex-py-client<0.2.0,>=0.1.18 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.1.19)\n",
            "Requirement already satisfied: nest-asyncio<2.0.0,>=1.5.8 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.6.0)\n",
            "Requirement already satisfied: networkx>=3.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.3)\n",
            "Requirement already satisfied: nltk<4.0.0,>=3.8.1 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.8.1)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.25.2)\n",
            "Requirement already satisfied: openai>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.30.1)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.0.3)\n",
            "Requirement already satisfied: pillow>=9.0.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (9.4.0)\n",
            "Requirement already satisfied: requests>=2.31.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.31.0)\n",
            "Requirement already satisfied: spacy<4.0.0,>=3.7.1 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.7.4)\n",
            "Requirement already satisfied: tenacity<9.0.0,>=8.2.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (8.3.0)\n",
            "Requirement already satisfied: tiktoken>=0.3.3 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.7.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.66.1 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (4.66.4)\n",
            "Requirement already satisfied: typing-extensions>=4.5.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (4.11.0)\n",
            "Requirement already satisfied: typing-inspect>=0.8.0 in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.9.0)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.10/dist-packages (from llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.14.1)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (23.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.9.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.6->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (4.0.3)\n",
            "Requirement already satisfied: ply in /usr/local/lib/python3.10/dist-packages (from jsonpath-ng<2.0.0,>=1.6.0->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.11)\n",
            "Requirement already satisfied: pydantic>=1.10 in /usr/local/lib/python3.10/dist-packages (from llamaindex-py-client<0.2.0,>=0.1.18->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.10.11)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.7.1)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2024.2.2)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.0.5)\n",
            "Requirement already satisfied: idna in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.7)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.14.0)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk<4.0.0,>=3.8.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2023.12.25)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai>=1.1.0->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.7.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.31.0->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.3.2)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.31.0->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.0.7)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (8.2.3)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.1.2)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.4.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.3.4)\n",
            "Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.9.4)\n",
            "Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (6.4.0)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.1.4)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (67.7.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (24.0)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.4.0)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy[asyncio]>=1.4.49->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.0.3)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect>=0.8.0->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.0.0)\n",
            "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (3.21.2)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2023.4)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2024.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.2.1)\n",
            "Requirement already satisfied: language-data>=1.2 in /usr/local/lib/python3.10/dist-packages (from langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.2.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.16.0)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.1.4)\n",
            "Requirement already satisfied: cloudpathlib<0.17.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.4.0,>=0.1.0->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (0.16.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (2.1.5)\n",
            "Requirement already satisfied: marisa-trie>=0.7.7 in /usr/local/lib/python3.10/dist-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.7.1->llama-index-core<0.11.0,>=0.10.1->llama-index-embeddings-together) (1.1.1)\n",
            "Installing collected packages: llama-index-embeddings-together\n",
            "Successfully installed llama-index-embeddings-together-0.1.3\n",
            "Collecting voyageai\n",
            "  Downloading voyageai-0.2.2-py3-none-any.whl (19 kB)\n",
            "Requirement already satisfied: aiohttp<4.0,>=3.5 in /usr/local/lib/python3.10/dist-packages (from voyageai) (3.9.5)\n",
            "Collecting aiolimiter<2.0.0,>=1.1.0 (from voyageai)\n",
            "  Downloading aiolimiter-1.1.0-py3-none-any.whl (7.2 kB)\n",
            "Requirement already satisfied: numpy>=1.11 in /usr/local/lib/python3.10/dist-packages (from voyageai) (1.25.2)\n",
            "Requirement already satisfied: requests<3.0,>=2.20 in /usr/local/lib/python3.10/dist-packages (from voyageai) (2.31.0)\n",
            "Requirement already satisfied: tenacity>=8.0.1 in /usr/local/lib/python3.10/dist-packages (from voyageai) (8.3.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (23.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (1.9.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0,>=3.5->voyageai) (4.0.3)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0,>=2.20->voyageai) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0,>=2.20->voyageai) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0,>=2.20->voyageai) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0,>=2.20->voyageai) (2024.2.2)\n",
            "Installing collected packages: aiolimiter, voyageai\n",
            "Successfully installed aiolimiter-1.1.0 voyageai-0.2.2\n"
          ]
        }
      ],
      "source": [
        "!pip config --user set global.progress_bar off\n",
        "%pip install -qqq llama-index-vector-stores-pinecone\n",
        "!pip install -qqq sentence-transformers\n",
        "!pip install -qqq pydantic==1.10.11 pinecone-client>=3.0.0\n",
        "%pip install llama-index-embeddings-together\n",
        "!pip install -U voyageai"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "metadata": {
        "id": "9GKnbat3FbWZ"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "JAYMlvgoFj9V",
        "outputId": "27d84b4a-9dba-443e-d164-208cd3aa1323"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            question  ID\n",
              "0  What factors make Actinium Pharmaceuticals (AT...   0\n",
              "1  What potential impact could Vertex Pharmaceuti...   1\n",
              "2  What potential impact could Actinium Pharmaceu...   2\n",
              "3  How does the integration of cryptocurrency wal...   3\n",
              "4  Question: How can individuals utilize decentra...   4"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-500c4f80-a3f2-4f83-b7cc-3eb09440ed9d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>question</th>\n",
              "      <th>ID</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>What factors make Actinium Pharmaceuticals (AT...</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>What potential impact could Vertex Pharmaceuti...</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>What potential impact could Actinium Pharmaceu...</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>How does the integration of cryptocurrency wal...</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Question: How can individuals utilize decentra...</td>\n",
              "      <td>4</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-500c4f80-a3f2-4f83-b7cc-3eb09440ed9d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-500c4f80-a3f2-4f83-b7cc-3eb09440ed9d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-500c4f80-a3f2-4f83-b7cc-3eb09440ed9d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-ef88b639-f249-4df5-9143-909d547eec99\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ef88b639-f249-4df5-9143-909d547eec99')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-ef88b639-f249-4df5-9143-909d547eec99 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_test",
              "summary": "{\n  \"name\": \"df_test\",\n  \"rows\": 1233,\n  \"fields\": [\n    {\n      \"column\": \"question\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1233,\n        \"samples\": [\n          \"What factors contributed to Leidos Holdings, Inc.'s strong financial performance in the fourth quarter of 2023, and how do they plan to maintain this growth in the year ahead?\",\n          \"Question: How does the placement of cookies on your device affect your privacy and personal data?\",\n          \"What potential impact do the diverse ratings and price objectives given by various research analysts have on investor confidence in Aclaris Therapeutics' stock?\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 356,\n        \"min\": 0,\n        \"max\": 1232,\n        \"num_unique_values\": 1233,\n        \"samples\": [\n          355,\n          545,\n          802\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 5
        }
      ],
      "source": [
        "df_test = pd.read_csv(\"/content/all_questions_test_public.csv\")\n",
        "df_test.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "eArB9kEvGCBA",
        "outputId": "4a4b9369-c521-47ca-dd62-0dd46f1a6d59"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            raw_text  answer_id\n",
              "0  COLLEGE PARK, Md., April 05, 2024--(BUSINESS W...          0\n",
              "1  Wirestock\\n\\nNo matter the positive projection...          1\n",
              "2  Loading... Loading...\\n\\nClinical-stage psyche...          2\n",
              "3  In the phase IIb expansion, patients will be r...          3\n",
              "4  \\n\\n\\n\\n\\n\\nSequans to Showcase its Cellular I...          4"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-580afc52-90ce-4b0f-9987-96b13e1a6feb\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>raw_text</th>\n",
              "      <th>answer_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>COLLEGE PARK, Md., April 05, 2024--(BUSINESS W...</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Wirestock\\n\\nNo matter the positive projection...</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Loading... Loading...\\n\\nClinical-stage psyche...</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>In the phase IIb expansion, patients will be r...</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>\\n\\n\\n\\n\\n\\nSequans to Showcase its Cellular I...</td>\n",
              "      <td>4</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-580afc52-90ce-4b0f-9987-96b13e1a6feb')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-580afc52-90ce-4b0f-9987-96b13e1a6feb button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-580afc52-90ce-4b0f-9987-96b13e1a6feb');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-10f9bebd-890f-44e2-8974-bd1805905676\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-10f9bebd-890f-44e2-8974-bd1805905676')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-10f9bebd-890f-44e2-8974-bd1805905676 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_test_a",
              "summary": "{\n  \"name\": \"df_test_a\",\n  \"rows\": 1233,\n  \"fields\": [\n    {\n      \"column\": \"raw_text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1233,\n        \"samples\": [\n          \"DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS\\u00ae platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer. This is the first in a series of payments, with Precision to receive a total of $17.5 million in upfront and potential near-term payments as part of the consideration for this license.\\n\\nIn exchange for global rights to azer-cel for autoimmune diseases and indications outside of cancer, Precision has received an upfront payment totaling $7.5 million , consisting of cash and the purchase of 2,920,816 shares of Precision common stock by TG Therapeutics at a price of $0.77 per share, a 100% premium to the 30-day volume-weighted average price (VWAP) prior to purchase.\\n\\nPrecision will also receive an additional $2.5 million within 11 months, as an equity investment in Precision\\u2019s common stock at 100% premium to the then 30-day VWAP prior to purchase. Upon the achievement of certain near-term clinical milestones, Precision will also receive an additional $7.5 million payment. Precision is eligible to receive up to $288 million in milestone payments in addition to high-single-digit to low-double-digit royalties on net sales.\\n\\nPrecision expects that these recent payments from its azer-cel transactions, along with existing cash and cash equivalents, expected operational receipts, continued fiscal and operating discipline, and availability of Precision\\u2019s at-the-market (ATM) facility will extend Precision\\u2019s cash runway into the first half of 2026, through phase 1 clinical readouts for its wholly owned programs.\\n\\nAbout Precision BioSciences, Inc.\\n\\nPrecision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\\u00ae genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company\\u2019s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences , please visit www.precisionbiosciences.com.\\n\\nForward-Looking Statements\\n\\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our product candidates (including azer-cel) and gene editing approaches including editing efficiency and differentiating aspects; the suitability of azer-cel for oncology indications and non-oncology indications including immunological diseases; expectations about our operational initiatives and business strategy; our expected cash runway; expectations about achievement of key milestones and receipt of any milestone, royalty, or other payments; expectations regarding our liquidity and capital resources; and anticipated timing of initial clinical data. In some cases, you can identify forward-looking statements by terms such as \\u201caim,\\u201d \\u201canticipate,\\u201d \\u201capproach,\\u201d \\u201cbelieve,\\u201d \\u201ccontemplate,\\u201d \\u201ccould,\\u201d \\u201cestimate,\\u201d \\u201cexpect,\\u201d \\u201cgoal,\\u201d \\u201cintend,\\u201d \\u201clook,\\u201d \\u201cmay,\\u201d \\u201cmission,\\u201d \\u201cplan,\\u201d \\u201cpossible,\\u201d \\u201cpotential,\\u201d \\u201cpredict,\\u201d \\u201cproject,\\u201d \\u201cpursue,\\u201d \\u201cshould,\\u201d \\u201ctarget,\\u201d \\u201cwill,\\u201d \\u201cwould,\\u201d or the negative thereof and similar words and expressions.\\n\\nForward-looking statements are based on management\\u2019s current expectations, beliefs and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators\\u2019 or other licensees\\u2019 ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators\\u2019 or other licensees\\u2019 development of product candidates; our or our collaborators\\u2019 or other licensees\\u2019 ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; delays or difficulties in our and our collaborators\\u2019 and other licensees\\u2019 ability to enroll patients; changes in interim \\u201ctop-line\\u201d and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees\\u2019 ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators\\u2019 or other licensees\\u2019 ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of the COVID-19 pandemic and variants thereof, or any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption \\u201cRisk Factors\\u201d in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 , as any such factors may be updated from time to time in our other filings with the SEC , which are accessible on the SEC\\u2019s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.\\n\\nAll forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\\n\\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240212039949/en/\\n\\nInvestor and Media Contact:\\n\\nNaresh Tanna\\n\\nVice President of Investor Relations\\n\\nNaresh.Tanna@Precisionbiosciences.com\",\n          \"Ad Prosper Trading Academy\\n\\nBuy Alert: Get these AI trades on repeat\\n\\nWith this AI Trade Finder, one of my newer students took his trading account from $1,500 to over $9,400 in just over a month\\n\\nClick Here To Get My Daily List of AI Generated Trades\",\n          \"Alphabet Inc.'s (GOOG) stock has been on the rise, reaching all-time highs following the announcement of its plan to increase in-house chip production. The Wall Street Journal reported that the tech giant is looking to manufacture more semiconductors under its roof, expanding on its first semi-custom mobile chip, Tensor, which debuted in 2020 on the Google Pixel 6.\\n\\nThe new chip, dubbed Axion, will primarily be used for cloud AI workloads and is set to challenge industry leaders such as Intel (INTC), NVIDIA (NVDA), and Advanced Micro (AMD).\\n\\nIncreased Efficiency and Dependence on Foundries:\\n\\nBy designing its own chips and relying on Intel or Taiwan Semiconductor (TSM) for manufacturing, Alphabet can achieve efficiency and productivity gains, essential for embedding more AI features in devices.\\n\\nThe company's move into chip production is not intended to compete with the likes of Intel and NVIDIA but rather to coexist in the industry, particularly in the AI sector.\\n\\nBenefits for Suppliers and Competition:\\n\\nAlphabet's increased in-house chip production could significantly benefit suppliers Broadcom (AVGO) and Qualcomm (QCOM), as the company has already tapped Broadcom for its Tensor chips, and recently expanded its partnership with Qualcomm revolving around mixed reality.\\n\\nWhile the move could streamline Alphabet's supply chain and reduce its reliance on third-party chip manufacturers, it may also intensify competition in the AI space, as industry leaders such as NVIDIA, AMD, and Intel could lose market share to the tech giant.\\n\\nThe Google Axion Processor:\\n\\nAxion is the latest in a long line of custom Google silicon, following the release of five generations of Tensor Processing Units (TPU) since 2015. The Axion processors, built using the Arm Neoverse V2 CPU, deliver instances with up to 30% better performance than the fastest general-purpose Arm-based instances available in the cloud today, up to 50% better performance and up to 60% better energy-efficiency compared to current-generation x86-based instances.\\n\\nAxion's Underpinnings:\\n\\nAxion is underpinned by Titanium, a system of custom silicon microcontrollers and tiered scale-out offloads. Titanium offloads networking and security operations, freeing up capacity and improving performance for customer workloads. It also offloads storage I/O processing to Hyperdisk, a new block storage service that decouples performance from instance size and can be provisioned in real-time.\\n\\nConclusion:\\n\\nAlphabet's investment in in-house chip production and the unveiling of the Google Axion Processor signify the company's commitment to streamline its supply chain, reduces reliance on third-party chip manufacturers, and bring significant efficiency enhancements.\\n\\nWhile the move could intensify competition in the AI space, it also has the potential to benefit suppliers such as Broadcom and Qualcomm. As the race to lead in AI continues, it will be interesting to see if Alphabet expands its in-house chip production further.\\n\\nInvestment Takeaway:\\n\\nAlphabet's (GOOG) growth potential is continues strengthened by its focus on in-house chip production and the release of the Google Axion Processor. This move could lead to increased efficiency, reduced dependence on third-party manufacturers, and significant benefits for suppliers. As the company to invest in AI technology, it remains to be seen how this will impact its competition in the industry and how it will shape the future of the chip market.\\n\\n\\n\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"answer_id\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 356,\n        \"min\": 0,\n        \"max\": 1232,\n        \"num_unique_values\": 1233,\n        \"samples\": [\n          355,\n          545,\n          802\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ],
      "source": [
        "df_test_a = pd.read_csv(\"/content/all_answers_test_public.csv\")\n",
        "df_test_a.head()"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# pinecone"
      ],
      "metadata": {
        "id": "eRKLVijYe7ri"
      }
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "metadata": {
        "id": "3CplXFiNulAm"
      },
      "outputs": [],
      "source": [
        "from pinecone import Pinecone\n",
        "pc = Pinecone(api_key = pine)\n",
        "pinecone_index = pc.Index(\"fin\")"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# pinecone_index.delete(delete_all=True, namespace='ns1')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "H_rfm-urey-C",
        "outputId": "c3209509-3ea5-471b-9f88-6369567c36d2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{}"
            ]
          },
          "metadata": {},
          "execution_count": 346
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# pinecone_index.upsert(pl[1000:], namespace = \"ns1\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "o8wEY-vJfC2S",
        "outputId": "7417d9a2-e6f5-4d0e-ca71-37a6e2060f6d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'upserted_count': 233}"
            ]
          },
          "metadata": {},
          "execution_count": 360
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "l = []\n",
        "for i in range(len(embeddings_q)):\n",
        "  l.append(int(pinecone_index.query(\n",
        "    namespace=\"ns1\",\n",
        "    vector=embeddings_q[i],\n",
        "    top_k=1,\n",
        "     include_metadata=True\n",
        ").matches[0]['id']))"
      ],
      "metadata": {
        "id": "Wiik2Xuy7VET"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.Series(l).to_csv(\"result.csv\")"
      ],
      "metadata": {
        "id": "ntFjiOHW35Xe"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.Series(l).to_csv(\"result.csv\")"
      ],
      "metadata": {
        "id": "DANCVMfRFeFk"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.read_csv(\"result.csv\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "-tOb8H2HGGqA",
        "outputId": "96285a7b-63de-411d-e6d5-e627f8ab32ac"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "      Unnamed: 0     0\n",
              "0              0  1112\n",
              "1              1  1047\n",
              "2              2   363\n",
              "3              3   731\n",
              "4              4   328\n",
              "...          ...   ...\n",
              "1228        1228   923\n",
              "1229        1229  1057\n",
              "1230        1230   625\n",
              "1231        1231   973\n",
              "1232        1232   285\n",
              "\n",
              "[1233 rows x 2 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-489f41ea-9d47-47df-8e81-2904623da434\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>0</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>1112</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>1047</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2</td>\n",
              "      <td>363</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>3</td>\n",
              "      <td>731</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>4</td>\n",
              "      <td>328</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1228</th>\n",
              "      <td>1228</td>\n",
              "      <td>923</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1229</th>\n",
              "      <td>1229</td>\n",
              "      <td>1057</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1230</th>\n",
              "      <td>1230</td>\n",
              "      <td>625</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1231</th>\n",
              "      <td>1231</td>\n",
              "      <td>973</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1232</th>\n",
              "      <td>1232</td>\n",
              "      <td>285</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1233 rows × 2 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-489f41ea-9d47-47df-8e81-2904623da434')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-489f41ea-9d47-47df-8e81-2904623da434 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-489f41ea-9d47-47df-8e81-2904623da434');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-95ae7ae7-5079-4fb4-9024-b47d963c7ed7\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-95ae7ae7-5079-4fb4-9024-b47d963c7ed7')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-95ae7ae7-5079-4fb4-9024-b47d963c7ed7 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"pd\",\n  \"rows\": 1233,\n  \"fields\": [\n    {\n      \"column\": \"Unnamed: 0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 356,\n        \"min\": 0,\n        \"max\": 1232,\n        \"num_unique_values\": 1233,\n        \"samples\": [\n          355,\n          545,\n          802\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 351,\n        \"min\": 0,\n        \"max\": 1232,\n        \"num_unique_values\": 1078,\n        \"samples\": [\n          740,\n          395,\n          354\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 363
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "N1R9WH4ByYun"
      },
      "source": [
        "#voyager\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {
        "id": "bxBBm2uOyZY7"
      },
      "outputs": [],
      "source": [
        "import voyageai\n",
        "vo = voyageai.Client(api_key = voy)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "metadata": {
        "id": "pWXV1y37ZJP-"
      },
      "outputs": [],
      "source": [
        "doc_a = df_test_a.raw_text.to_list()\n",
        "doc_q = df_test.question.to_list()\n",
        "e_a = pd.read_csv(\"series_a.csv\").iloc[:, 1:]\n",
        "e_q =  pd.read_csv(\"series_q.csv\").iloc[:, 1:]\n",
        "e_q = pd.Series(e_q[\"0\"]).tolist()\n",
        "e_a = pd.Series(e_a[\"0\"]).tolist()"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "answer embedding\n"
      ],
      "metadata": {
        "id": "q8qmxSyJ8ITw"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "lRxIWVN_0ITc"
      },
      "outputs": [],
      "source": [
        "# Answers\n",
        "batch_size = 50\n",
        "embeddings = []\n",
        "\n",
        "for i in range(0, len(doc_a), batch_size):\n",
        "    embeddings += vo.embed(\n",
        "        doc_a[i:i + batch_size], model=\"voyage-large-2-instruct\", input_type=\"document\"\n",
        "    ).embeddings"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# pd.Series(embeddings_q).to_csv('series_q.csv')"
      ],
      "metadata": {
        "id": "vOX0IvOR3-0J"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "question embedding"
      ],
      "metadata": {
        "id": "8K90Lq0o8J75"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "k8NPoEesVPlL"
      },
      "outputs": [],
      "source": [
        "# Questions\n",
        "embeddings_q = []\n",
        "\n",
        "for i in range(0, len(doc_q)):\n",
        "    embeddings_q += vo.embed(\n",
        "        doc_q[i], model=\"voyage-large-2-instruct\", input_type=\"document\"\n",
        "    ).embeddings"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "json"
      ],
      "metadata": {
        "id": "Z7dJSmZsC9aS"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "pl = []\n",
        "for i in range(len(e_a)):\n",
        "\n",
        "  pl.append( {\n",
        "       \"id\": str(i),\n",
        "        \"values\": e_a[i],\n",
        "        \"metadata\" : { \"text\" : doc_a[i]}\n",
        "\n",
        "  })"
      ],
      "metadata": {
        "id": "92qwawzjC-2p"
      },
      "execution_count": 13,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# r = []\n",
        "# for i in range(len(embeddings_q)):\n",
        "#   r.append(int(pinecone_index.query(\n",
        "#     namespace=\"ns1\",\n",
        "#     vector=embeddings_q[i],\n",
        "#     top_k=1,\n",
        "#      include_metadata=True\n",
        "# ).matches[0]['id']))"
      ],
      "metadata": {
        "id": "SafAvPa3JSoH"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Rerankers"
      ],
      "metadata": {
        "id": "4deiO7s1JTAm"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "r = []\n",
        "for i in range(len(e_q)):\n",
        "  r.append(pinecone_index.query(\n",
        "      namespace=\"ns1\",\n",
        "      vector=eval(e_q[i]),\n",
        "      top_k=10,\n",
        "      include_metadata=True ))\n",
        "  # ).matches[i].metadata['text'])"
      ],
      "metadata": {
        "id": "4Xb7wHJjKBwk"
      },
      "execution_count": 17,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "r"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ku2jt1QKDXTH",
        "outputId": "81683b12-ef11-45e9-8232-a8b04b75090c"
      },
      "execution_count": 36,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'matches': [{'id': '1112',\n",
              "              'metadata': {'text': 'Biotech Stocks Taking Centerstage\\n'\n",
              "                                   '\\n'\n",
              "                                   'As the pharmaceutical industry ventures '\n",
              "                                   'deeper into the era of precision medicine, '\n",
              "                                   'radiopharmaceuticals, particularly those '\n",
              "                                   'involving alpha emitters like Actinium-225 '\n",
              "                                   '(Ac-225), are gaining prominence for their '\n",
              "                                   'targeted approach to cancer treatment. '\n",
              "                                   'Amid this innovative surge, Actinium '\n",
              "                                   'Pharmaceuticals (NYSE:ATNM) emerges not '\n",
              "                                   'just as a company with a promising '\n",
              "                                   'pipeline but as a beacon of cutting-edge '\n",
              "                                   'manufacturing capabilities that could very '\n",
              "                                   'well position it as a prime buyout '\n",
              "                                   'candidate in the eyes of investors and '\n",
              "                                   'industry giants alike.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Actinium Pharmaceuticals (NYSE:ATNM) '\n",
              "                                   'recently announced a pivotal strategic '\n",
              "                                   'initiative to escalate the production of '\n",
              "                                   'Ac-225 using a proprietary cyclotron-based '\n",
              "                                   'method, as detailed in a press release '\n",
              "                                   'from March 11, 2024. This method not only '\n",
              "                                   'promises high-purity Ac-225 but also '\n",
              "                                   'boasts the potential for significantly '\n",
              "                                   'lower costs and higher yields compared to '\n",
              "                                   'the traditional Thorium-229 generator '\n",
              "                                   'method. The significance of this '\n",
              "                                   'development cannot be overstated, given '\n",
              "                                   'the isotope’s remarkable ability to kill '\n",
              "                                   'targeted cancer cells without known '\n",
              "                                   'resistance or repair mechanisms, courtesy '\n",
              "                                   'of its high linear energy transfer and '\n",
              "                                   'capacity for inducing double-strand breaks '\n",
              "                                   'in DNA.\\n'\n",
              "                                   '\\n'\n",
              "                                   'This initiative is not merely about '\n",
              "                                   \"enhancing Actinium's manufacturing \"\n",
              "                                   \"prowess; it's an outright game-changer. \"\n",
              "                                   \"The company's intellectual property \"\n",
              "                                   'portfolio, encompassing 5 issued U.S. '\n",
              "                                   'patents and 49 international patents, '\n",
              "                                   'coupled with extensive technical know-how, '\n",
              "                                   'places Actinium at the forefront of a '\n",
              "                                   'radiopharmaceutical revolution. With the '\n",
              "                                   'capability to produce up to 100 mCi of '\n",
              "                                   'Ac-225 per production cycle at a cost '\n",
              "                                   'estimated to be 10 to 20 times lower than '\n",
              "                                   'current methods, and with radiochemical '\n",
              "                                   \"purity exceeding 99%, Actinium's \"\n",
              "                                   'production technology sets a new standard '\n",
              "                                   'in the industry.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The broader context of this development is '\n",
              "                                   'the recent flurry of acquisitions in the '\n",
              "                                   \"radiopharma space, notably AstraZeneca's \"\n",
              "                                   '(NASDAQ:AZN) acquisition of Fusion Pharma '\n",
              "                                   \"and Bristol Meyers's (NYSE:BMY) $4.1 \"\n",
              "                                   'billion acquisition of RayzeBio for its '\n",
              "                                   'Ac-225 pipeline, highlighting the '\n",
              "                                   'strategic importance of alpha emitters. '\n",
              "                                   \"Furthermore, Lilly's acquisition of POINT \"\n",
              "                                   'Biopharma for $1.4 billion emphasizes the '\n",
              "                                   'burgeoning interest in targeted '\n",
              "                                   'radiotherapies. In this landscape, '\n",
              "                                   \"Actinium's strategic initiative \"\n",
              "                                   'underscores its scarcity value and '\n",
              "                                   'technological edge, making it a compelling '\n",
              "                                   'target for companies vying for dominance '\n",
              "                                   'in next-generation cancer therapies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'For investors and traders, the allure of '\n",
              "                                   'Actinium Pharmaceuticals is twofold: the '\n",
              "                                   'immediate potential for growth driven by '\n",
              "                                   'its advanced manufacturing capabilities '\n",
              "                                   'and the long-term prospect of becoming a '\n",
              "                                   'buyout target in an industry segment '\n",
              "                                   'marked by high-stakes acquisitions. '\n",
              "                                   \"Actinium's focus on a niche yet \"\n",
              "                                   'explosively growing segment of '\n",
              "                                   'radiopharmaceuticals, coupled with its '\n",
              "                                   'innovative production method, positions it '\n",
              "                                   'as a strategic asset in the race to '\n",
              "                                   'harness the power of targeted cancer '\n",
              "                                   'therapies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Actinium Pharmaceuticals (ATNM) '\n",
              "                                   'potentially represents an unparalleled '\n",
              "                                   'investment opportunity, not just for its '\n",
              "                                   'promising pipeline but for its '\n",
              "                                   'groundbreaking approach to the production '\n",
              "                                   'of Ac-225. As the radiopharma sector '\n",
              "                                   'continues to attract significant interest '\n",
              "                                   'and investment, Actinium stands out as a '\n",
              "                                   'company with both immediate impact and '\n",
              "                                   'strategic value, making it an attractive '\n",
              "                                   'proposition for those looking to invest in '\n",
              "                                   'the forefront of medical innovation. The '\n",
              "                                   'company’s recent strategic initiative '\n",
              "                                   'marks a significant milestone, potentially '\n",
              "                                   'catalyzing its journey towards becoming a '\n",
              "                                   'coveted acquisition target amidst the '\n",
              "                                   'radiopharmaceutical acquisition wave.\\n'\n",
              "                                   '\\n'\n",
              "                                   'On Monday, the biotech sector displayed a '\n",
              "                                   'mix of performances among its leading '\n",
              "                                   'stocks. Novo Nordisk A/S (NYSE:NVO) saw a '\n",
              "                                   'modest increase of 0.29, reaching 129.05 '\n",
              "                                   '(+0.23%), with trading volume at 3.305M '\n",
              "                                   'against an average of 5.126M, showcasing a '\n",
              "                                   'market cap of 577.833B and a PE ratio of '\n",
              "                                   '47.27. Vertex Pharmaceuticals Incorporated '\n",
              "                                   '(NASDAQ:VRTX) slightly rose by 0.37 to '\n",
              "                                   '416.03 (+0.09%), with a trading volume of '\n",
              "                                   '721,971 compared to its average of 1.303M, '\n",
              "                                   'holding a market valuation of 107.464B and '\n",
              "                                   'a PE ratio of 29.97. Regeneron '\n",
              "                                   'Pharmaceuticals, Inc. (NASDAQ:REGN) '\n",
              "                                   'experienced a decrease, dropping by 6.15 '\n",
              "                                   'to 961.09 (-0.64%), with its volume at '\n",
              "                                   '315,100 versus an average of 522,886, and '\n",
              "                                   'a market cap of 105.491B, with a PE ratio '\n",
              "                                   'of 27.67. Moderna, Inc. (MRNA) notably '\n",
              "                                   'surged by 4.95 to 110.38 (+4.70%), trading '\n",
              "                                   '3.54M shares against an average of 4.459M, '\n",
              "                                   'resulting in a market cap of 42.262B. '\n",
              "                                   'argenx SE (NASDAQ:ARGX) fell by 4.26 to '\n",
              "                                   '398.42 (-1.06%), with a volume of 179,831 '\n",
              "                                   'and an average of 362,027, and a market '\n",
              "                                   'cap of 23.867B. BioNTech SE (NASDAQ:BNTX) '\n",
              "                                   'increased by 1.17 to 93.00 (+1.27%), with '\n",
              "                                   'a trading volume of 371,817 compared to an '\n",
              "                                   'average of 698,642, and a market '\n",
              "                                   'capitalization of 22.109B, alongside a PE '\n",
              "                                   'ratio of 22.20.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Disclaimer: This blog post is for '\n",
              "                                   'informational purposes only and does not '\n",
              "                                   'constitute financial advice or an '\n",
              "                                   'endorsement of ATNM or its strategies. FOR '\n",
              "                                   'EDUCATIONAL AND INFORMATION PURPOSES ONLY; '\n",
              "                                   'NOT INVESTMENT ADVICE. Please ensure to '\n",
              "                                   'fully read and comprehend our disclaimer '\n",
              "                                   'found at '\n",
              "                                   'https://investorbrandmedia.com/disclaimer/. '\n",
              "                                   'InvestorBrandMedia.com has been '\n",
              "                                   'compensated five hundred dollars by a 3rd '\n",
              "                                   'party Bullzeyemedia LLC for content '\n",
              "                                   'distribution services on ATNM for March '\n",
              "                                   '20th, 2024. We own zero shares of ATNM. '\n",
              "                                   'InvestorBrandMedia.com is neither an '\n",
              "                                   'investment advisor nor a registered '\n",
              "                                   'broker. No current owner, employee, or '\n",
              "                                   'independent contractor of '\n",
              "                                   'InvestorBrandMedia.com is registered as a '\n",
              "                                   'securities broker-dealer, broker, '\n",
              "                                   'investment advisor, or IA representative '\n",
              "                                   'with the U.S. Securities and Exchange '\n",
              "                                   'Commission, any state securities '\n",
              "                                   'regulatory authority, or any '\n",
              "                                   'self-regulatory organization. This article '\n",
              "                                   'may contain forward-looking statements as '\n",
              "                                   'defined under Section 27A of the '\n",
              "                                   'Securities Act of 1933 and 21E of the '\n",
              "                                   'Exchange Act of 1934. These statements, '\n",
              "                                   'often incorporating terms like “believes,” '\n",
              "                                   '“anticipates,” “estimates,” “expects,” '\n",
              "                                   '“projects,” “intends,” or similar '\n",
              "                                   'expressions about future performance or '\n",
              "                                   'conduct, are based on present '\n",
              "                                   'expectations, estimates, and projections, '\n",
              "                                   'and are not historical facts. They carry '\n",
              "                                   'various risks and uncertainties that may '\n",
              "                                   'result in significant deviation from the '\n",
              "                                   'anticipated results or events. Past '\n",
              "                                   'performance does not guarantee future '\n",
              "                                   'results.InvestorBrandMedia.com does not '\n",
              "                                   'commit to updating forward-looking '\n",
              "                                   'statements based on new information or '\n",
              "                                   'future events. Readers are encouraged to '\n",
              "                                   'review all public SEC filings made by the '\n",
              "                                   'profiled companies at '\n",
              "                                   'https://www.sec.gov/edgar/searchedgar/companysearch. '\n",
              "                                   'It is always important to conduct thorough '\n",
              "                                   'due diligence and exercise caution in '\n",
              "                                   'trading.InvestorBrandMedia.com is not '\n",
              "                                   'managed by a licensed broker, a dealer, or '\n",
              "                                   'a registered investment adviser. The '\n",
              "                                   'content here is purely informational and '\n",
              "                                   'should not be taken as investment advice. '\n",
              "                                   'The Private Securities Litigation Reform '\n",
              "                                   'Act of 1995 provides investors a safe '\n",
              "                                   'harbor regarding forward-looking '\n",
              "                                   'statements. Any statement that projects, '\n",
              "                                   'foresees, expects, anticipates, estimates, '\n",
              "                                   'believes, or understands certain actions '\n",
              "                                   'to possibly occur are not historical facts '\n",
              "                                   'and may be forward-looking statements. '\n",
              "                                   'These statements are based on '\n",
              "                                   'expectations, estimates, and projections '\n",
              "                                   'that could cause actual results to differ '\n",
              "                                   'greatly from those anticipated. Investing '\n",
              "                                   'in micro-cap and growth securities is '\n",
              "                                   'speculative and entails a high degree of '\n",
              "                                   'risk, potentially leading to a total or '\n",
              "                                   'substantial loss of investment. Please '\n",
              "                                   'note that no content published here '\n",
              "                                   'constitutes a recommendation to buy or '\n",
              "                                   'sell a security. It is solely '\n",
              "                                   'informational, and you should not construe '\n",
              "                                   'it as legal, tax, investment, financial, '\n",
              "                                   'or other advice. No content in this '\n",
              "                                   'article constitutes an offer or '\n",
              "                                   'solicitation by InvestorBrandMedia.com or '\n",
              "                                   'any third-party service provider to buy or '\n",
              "                                   'sell securities or other financial '\n",
              "                                   'instruments. The content in this article '\n",
              "                                   'does not address the circumstances of any '\n",
              "                                   'specific individual or entity and does not '\n",
              "                                   'constitute professional and/or financial '\n",
              "                                   'advice. InvestorBrandMedia.com is not a '\n",
              "                                   'fiduciary by virtue of any person’s use of '\n",
              "                                   'or access to this content.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Sources:\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://www.tipranks.com/news/the-fly/actinium-pharmaceuticals-price-target-raised-to-30-from-20-at-maxim\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/news/actinium-pharmaceuticals-launches-actinium-225-113000769.html\\n'\n",
              "                                   '\\n'\n",
              "                                   'Media Contact\\n'\n",
              "                                   '\\n'\n",
              "                                   'Company Name: Investor Brand Media\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact Person: Ash K\\n'\n",
              "                                   '\\n'\n",
              "                                   'Email: investorbrandmedia@gmail.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'Phone: (954) 593-5597\\n'\n",
              "                                   '\\n'\n",
              "                                   'Country: United States\\n'\n",
              "                                   '\\n'\n",
              "                                   'Website:https://investorbrandmedia.com/\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   'Press Release Distributed by '\n",
              "                                   'ABNewswire.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'To view the original version on ABNewswire '\n",
              "                                   'visit: Actinium Pharmaceuticals (ATNM): A '\n",
              "                                   'Prime Buyout Candidate Amidst a '\n",
              "                                   'Radiopharma Acquisition Wave'},\n",
              "              'score': 0.870061517,\n",
              "              'values': []},\n",
              "             {'id': '363',\n",
              "              'metadata': {'text': 'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   'Top Biotech Stocks\\n'\n",
              "                                   '\\n'\n",
              "                                   'In the rapidly advancing field of cellular '\n",
              "                                   'therapy, Actinium Pharmaceuticals, Inc. '\n",
              "                                   'ATNM has emerged as a trailblazer with its '\n",
              "                                   'latest announcement that promises to '\n",
              "                                   'reshape the landscape of cancer treatment. '\n",
              "                                   'As of March 26, 2024, from the heart of '\n",
              "                                   'New York, Actinium has revealed a '\n",
              "                                   'strategic collaboration with the '\n",
              "                                   'University of Texas Southwestern Medical '\n",
              "                                   'Center (UT Southwestern) to initiate a '\n",
              "                                   'clinical trial for Iomab-ACT, a '\n",
              "                                   'revolutionary targeted radiotherapy '\n",
              "                                   'conditioning agent. This pioneering study, '\n",
              "                                   'aimed at enhancing the efficacy of '\n",
              "                                   'FDA-approved commercial CAR T-cell '\n",
              "                                   'therapy, positions Actinium at the '\n",
              "                                   'forefront of innovation in targeted cancer '\n",
              "                                   'treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Why Investors and Traders Should Take '\n",
              "                                   'Notice\\n'\n",
              "                                   '\\n'\n",
              "                                   '1. Market Potential and Growth Trajectory: '\n",
              "                                   'The realm of CAR T-cell therapy represents '\n",
              "                                   'a rapidly growing market, with six '\n",
              "                                   'FDA-approved therapies that collectively '\n",
              "                                   'generated over $3.5 billion in sales in '\n",
              "                                   '2023 alone. These therapies offer '\n",
              "                                   'groundbreaking treatment options for '\n",
              "                                   'patients with leukemias, lymphomas, and '\n",
              "                                   'multiple myeloma. With an expected market '\n",
              "                                   'growth and the potential to nearly double '\n",
              "                                   'the patient population by 2030 in the '\n",
              "                                   'U.S., Actinium’s Iomab-ACT emerges as a '\n",
              "                                   'critical tool in this expanding field. Its '\n",
              "                                   'ability to improve patient access and '\n",
              "                                   'outcomes presents a substantial market '\n",
              "                                   'opportunity for Actinium, suggesting a '\n",
              "                                   'promising horizon for investors and '\n",
              "                                   'traders alike.\\n'\n",
              "                                   '\\n'\n",
              "                                   '2. Addressing a Critical Unmet Need: '\n",
              "                                   'Current CAR T-cell therapy protocols '\n",
              "                                   'necessitate chemotherapy-based '\n",
              "                                   'conditioning, which can cause severe '\n",
              "                                   'toxicities like ICANS and CRS, ultimately '\n",
              "                                   'limiting patient access to these '\n",
              "                                   \"life-saving treatments. Actinium's \"\n",
              "                                   'Iomab-ACT offers a targeted alternative '\n",
              "                                   'that aims to mitigate these toxicities, '\n",
              "                                   'potentially revolutionizing the '\n",
              "                                   'preconditioning process for CAR T-cell '\n",
              "                                   'therapies. This not only enhances the '\n",
              "                                   'safety and effectiveness of treatment but '\n",
              "                                   'also broadens patient eligibility - a '\n",
              "                                   'game-changer that underscores Actinium’s '\n",
              "                                   'potential for growth and profitability.\\n'\n",
              "                                   '\\n'\n",
              "                                   '3. Leadership in Innovation: Actinium’s '\n",
              "                                   'commitment to developing targeted '\n",
              "                                   'radiotherapies like Iomab-ACT and its '\n",
              "                                   'collaboration with esteemed institutions '\n",
              "                                   'like UT Southwestern underscore its '\n",
              "                                   'leadership position in the oncology field. '\n",
              "                                   \"The company's innovative approach, aiming \"\n",
              "                                   'to replace traditional chemotherapy '\n",
              "                                   'conditioning with targeted radiotherapy, '\n",
              "                                   'signifies a pivotal shift in cellular '\n",
              "                                   'therapy. Early clinical results showcasing '\n",
              "                                   \"Iomab-ACT's efficacy and safety further \"\n",
              "                                   \"validate Actinium's strategic direction, \"\n",
              "                                   'enhancing its appeal to investors looking '\n",
              "                                   'for companies at the cutting edge of '\n",
              "                                   'cancer treatment.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   '4. Financial Outlook and Revenue '\n",
              "                                   'Opportunity: With a substantial '\n",
              "                                   'addressable market for CAR T-cell and gene '\n",
              "                                   \"therapies, Actinium's Iomab-ACT \"\n",
              "                                   'potentially stands to capture significant '\n",
              "                                   'market share. The growing pipeline of '\n",
              "                                   'CAR-T and gene therapies, coupled with the '\n",
              "                                   'projected increase in the patient '\n",
              "                                   'population, positions Iomab-ACT as a '\n",
              "                                   'potential blockbuster revenue generator. '\n",
              "                                   \"The therapy's unique value proposition, \"\n",
              "                                   'aimed at reducing treatment-related '\n",
              "                                   'toxicities and improving outcomes, could '\n",
              "                                   'translate into a higher success rate for '\n",
              "                                   'cellular therapies, driving substantial '\n",
              "                                   'financial growth for Actinium.\\n'\n",
              "                                   '\\n'\n",
              "                                   'A Strategic Investment in the Future of '\n",
              "                                   'Oncology\\n'\n",
              "                                   '\\n'\n",
              "                                   'Actinium Pharmaceuticals, Inc. (ATNM) '\n",
              "                                   'potentially represents a compelling '\n",
              "                                   'investment opportunity for those looking '\n",
              "                                   'to capitalize on the future of oncology '\n",
              "                                   'treatments. With its pioneering Iomab-ACT '\n",
              "                                   'program, Actinium is not only advancing a '\n",
              "                                   'promising solution to a critical challenge '\n",
              "                                   'in CAR T-cell therapy but also positioning '\n",
              "                                   'itself for substantial market growth. For '\n",
              "                                   'traders and investors focused on '\n",
              "                                   'healthcare and biotechnology, ATNM offers '\n",
              "                                   'a unique blend of innovation, market '\n",
              "                                   'potential, and leadership in the '\n",
              "                                   'burgeoning field of cellular therapy. As '\n",
              "                                   'the company progresses with its clinical '\n",
              "                                   'trials and further demonstrates the '\n",
              "                                   'efficacy and safety of Iomab-ACT, Actinium '\n",
              "                                   'is poised to redefine cancer treatment and '\n",
              "                                   'deliver value to its stakeholders. '\n",
              "                                   'Further, Maxim raised the firm’s price '\n",
              "                                   'target on Actinium Pharmaceuticals to $30 '\n",
              "                                   'from $20 and keept a Buy rating on the '\n",
              "                                   'shares.\\n'\n",
              "                                   '\\n'\n",
              "                                   'A Potential Buyout Candidate\\n'\n",
              "                                   '\\n'\n",
              "                                   'Recent flurry of acquisitions in the '\n",
              "                                   \"radiopharma space, notably AstraZeneca's \"\n",
              "                                   'AZN acquisition of Fusion Pharma and '\n",
              "                                   \"Bristol Meyers's BMY $4.1 billion \"\n",
              "                                   'acquisition of RayzeBio for its Ac-225 '\n",
              "                                   'pipeline, highlighting the strategic '\n",
              "                                   'importance of alpha emitters. Furthermore, '\n",
              "                                   \"Lilly's acquisition of POINT Biopharma for \"\n",
              "                                   '$1.4 billion emphasizes the burgeoning '\n",
              "                                   'interest in targeted radiotherapies. In '\n",
              "                                   \"this landscape, Actinium's strategic \"\n",
              "                                   'initiative underscores its scarcity value '\n",
              "                                   'and technological edge, making it a '\n",
              "                                   'compelling target for companies vying for '\n",
              "                                   'dominance in next-generation cancer '\n",
              "                                   'therapies. As always, conduct your own due '\n",
              "                                   'diligence and follow traders vigilance.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Among the most active stocks at 2:25 pm '\n",
              "                                   'EST on Tuesday, Tilray Brands, Inc. TLRY '\n",
              "                                   'showcased a notable surge, trading at '\n",
              "                                   '$2.37 with a +10.23% change, driven by a '\n",
              "                                   'volume of 65.79M against an average of '\n",
              "                                   '24.31M, and a market cap of $1.79B. '\n",
              "                                   'Following closely, Nikola Corporation NKLA '\n",
              "                                   'registered a 10.26% increase at $0.8199, '\n",
              "                                   'with a trading volume of 107.12M, '\n",
              "                                   'significantly above its 3-month average of '\n",
              "                                   '90.20M, and a market cap of $1.10B. '\n",
              "                                   'Luminar Technologies, Inc. LAZR also made '\n",
              "                                   'the list, with a last price of $1.735, up '\n",
              "                                   'by 2.66%, and a trading volume of 10.00M '\n",
              "                                   'versus an average of 7.58M, with a market '\n",
              "                                   'capitalization of $731.97M. SNDL Inc. SNDL '\n",
              "                                   'observed a 13.87% jump to $1.97, on a '\n",
              "                                   'volume of 13.60M compared to its 3-month '\n",
              "                                   'average of 3.64M, and a market cap of '\n",
              "                                   '$518.28M. Lastly, Esperion Therapeutics, '\n",
              "                                   'Inc. ESPR climbed to $2.79, marking a '\n",
              "                                   '6.51% increase, with its volume at 13.01M '\n",
              "                                   'above the average of 6.17M, and a market '\n",
              "                                   'cap standing at $516.30M.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Sources:\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://www.tipranks.com/news/the-fly/actinium-pharmaceuticals-price-target-raised-to-30-from-20-at-maxim\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/news/actinium-announces-clinical-trial-study-111800504.html\\n'\n",
              "                                   '\\n'\n",
              "                                   'Disclaimer: This blog post is for '\n",
              "                                   'informational purposes only and does not '\n",
              "                                   'constitute financial advice or an '\n",
              "                                   'endorsement of ATNM or its strategies. FOR '\n",
              "                                   'EDUCATIONAL AND INFORMATION PURPOSES ONLY; '\n",
              "                                   'NOT INVESTMENT ADVICE. Please ensure to '\n",
              "                                   'fully read and comprehend our disclaimer '\n",
              "                                   'found at '\n",
              "                                   'https://investorbrandmedia.com/disclaimer/. '\n",
              "                                   'InvestorBrandMedia.com has been '\n",
              "                                   'compensated three thousand and five '\n",
              "                                   'hundred dollars by a 3rd party '\n",
              "                                   'Bullzeyemedia LLC for content distribution '\n",
              "                                   'services on ATNM for March 20th to March '\n",
              "                                   '28th, 2024. We own zero shares of ATNM. '\n",
              "                                   'InvestorBrandMedia.com is neither an '\n",
              "                                   'investment advisor nor a registered '\n",
              "                                   'broker. No current owner, employee, or '\n",
              "                                   'independent contractor of '\n",
              "                                   'InvestorBrandMedia.com is registered as a '\n",
              "                                   'securities broker-dealer, broker, '\n",
              "                                   'investment advisor, or IA representative '\n",
              "                                   'with the U.S. Securities and Exchange '\n",
              "                                   'Commission, any state securities '\n",
              "                                   'regulatory authority, or any '\n",
              "                                   'self-regulatory organization. This article '\n",
              "                                   'may contain forward-looking statements as '\n",
              "                                   'defined under Section 27A of the '\n",
              "                                   'Securities Act of 1933 and 21E of the '\n",
              "                                   'Exchange Act of 1934. These statements, '\n",
              "                                   'often incorporating terms like “believes,” '\n",
              "                                   '“anticipates,” “estimates,” “expects,” '\n",
              "                                   '“projects,” “intends,” or similar '\n",
              "                                   'expressions about future performance or '\n",
              "                                   'conduct, are based on present '\n",
              "                                   'expectations, estimates, and projections, '\n",
              "                                   'and are not historical facts. They carry '\n",
              "                                   'various risks and uncertainties that may '\n",
              "                                   'result in significant deviation from the '\n",
              "                                   'anticipated results or events. Past '\n",
              "                                   'performance does not guarantee future '\n",
              "                                   'results.InvestorBrandMedia.com does not '\n",
              "                                   'commit to updating forward-looking '\n",
              "                                   'statements based on new information or '\n",
              "                                   'future events. Readers are encouraged to '\n",
              "                                   'review all public SEC filings made by the '\n",
              "                                   'profiled companies at '\n",
              "                                   'https://www.sec.gov/edgar/searchedgar/companysearch. '\n",
              "                                   'It is always important to conduct thorough '\n",
              "                                   'due diligence and exercise caution in '\n",
              "                                   'trading.InvestorBrandMedia.com is not '\n",
              "                                   'managed by a licensed broker, a dealer, or '\n",
              "                                   'a registered investment adviser. The '\n",
              "                                   'content here is purely informational and '\n",
              "                                   'should not be taken as investment advice. '\n",
              "                                   'The Private Securities Litigation Reform '\n",
              "                                   'Act of 1995 provides investors a safe '\n",
              "                                   'harbor regarding forward-looking '\n",
              "                                   'statements. Any statement that projects, '\n",
              "                                   'foresees, expects, anticipates, estimates, '\n",
              "                                   'believes, or understands certain actions '\n",
              "                                   'to possibly occur are not historical facts '\n",
              "                                   'and may be forward-looking statements. '\n",
              "                                   'These statements are based on '\n",
              "                                   'expectations, estimates, and projections '\n",
              "                                   'that could cause actual results to differ '\n",
              "                                   'greatly from those anticipated. Investing '\n",
              "                                   'in micro-cap and growth securities is '\n",
              "                                   'speculative and entails a high degree of '\n",
              "                                   'risk, potentially leading to a total or '\n",
              "                                   'substantial loss of investment. Please '\n",
              "                                   'note that no content published here '\n",
              "                                   'constitutes a recommendation to buy or '\n",
              "                                   'sell a security. It is solely '\n",
              "                                   'informational, and you should not construe '\n",
              "                                   'it as legal, tax, investment, financial, '\n",
              "                                   'or other advice. No content in this '\n",
              "                                   'article constitutes an offer or '\n",
              "                                   'solicitation by InvestorBrandMedia.com or '\n",
              "                                   'any third-party service provider to buy or '\n",
              "                                   'sell securities or other financial '\n",
              "                                   'instruments. The content in this article '\n",
              "                                   'does not address the circumstances of any '\n",
              "                                   'specific individual or entity and does not '\n",
              "                                   'constitute professional and/or financial '\n",
              "                                   'advice. InvestorBrandMedia.com is not a '\n",
              "                                   'fiduciary by virtue of any person’s use of '\n",
              "                                   'or access to this content.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Media Contact\\n'\n",
              "                                   '\\n'\n",
              "                                   'Company Name: Investor Brand Media\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact Person: Ash K\\n'\n",
              "                                   '\\n'\n",
              "                                   'Email: investorbrandmedia@gmail.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'Phone: (954) 593-5597\\n'\n",
              "                                   '\\n'\n",
              "                                   'Country: United States\\n'\n",
              "                                   '\\n'\n",
              "                                   'Website: https://investorbrandmedia.com/\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   'Press Release Distributed by '\n",
              "                                   'ABNewswire.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'To view the original version on ABNewswire '\n",
              "                                   'visit: Actinium Pharmaceuticals (ATNM) '\n",
              "                                   'Spearheading the Future of Oncology with '\n",
              "                                   \"Iomab-ACT\\\\'s Innovative Clinical Trial\"},\n",
              "              'score': 0.828522205,\n",
              "              'values': []},\n",
              "             {'id': '1047',\n",
              "              'metadata': {'text': 'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   'Actinium Pharmaceuticals ATNM Launches '\n",
              "                                   'Actinium-225 Focused Strategic Initiative '\n",
              "                                   'to Leverage Proprietary Cyclotron Based '\n",
              "                                   'Manufacturing Technology to Address '\n",
              "                                   'Growing Market Demand\\n'\n",
              "                                   '\\n'\n",
              "                                   'In a significant stride toward addressing '\n",
              "                                   'one of the most challenging inherited '\n",
              "                                   'kidney diseases, Vertex Pharmaceuticals '\n",
              "                                   'Incorporated VRTX has recently made '\n",
              "                                   'headlines with its latest breakthrough in '\n",
              "                                   'the realm of medical science. The U.S. '\n",
              "                                   'Food and Drug Administration (FDA) has '\n",
              "                                   \"green-lighted Vertex's investigational new \"\n",
              "                                   'drug application, paving the way for the '\n",
              "                                   'clinical development of VX-407, a '\n",
              "                                   'promising candidate aimed at treating '\n",
              "                                   'autosomal dominant polycystic kidney '\n",
              "                                   'disease (ADPKD). This development marks a '\n",
              "                                   'monumental step for Vertex, as it plans to '\n",
              "                                   'initiate a phase I study on VX-407 in '\n",
              "                                   'ADPKD patients later this month.\\n'\n",
              "                                   '\\n'\n",
              "                                   'ADPKD is a common inherited kidney disease '\n",
              "                                   'characterized by the growth of numerous '\n",
              "                                   'kidney-enlarging cysts that impair kidney '\n",
              "                                   'function, potentially leading to kidney '\n",
              "                                   'failure or premature death. Currently, an '\n",
              "                                   'estimated 250,000 individuals in the '\n",
              "                                   'United States and Europe are afflicted '\n",
              "                                   'with ADPKD, a condition with no available '\n",
              "                                   'drugs to address its underlying cause. The '\n",
              "                                   'introduction of VX-407, a first-in-class '\n",
              "                                   'small molecule corrector, targets the '\n",
              "                                   'fundamental cause of ADPKD, offering a '\n",
              "                                   'beacon of hope for those suffering from '\n",
              "                                   'this debilitating disease.\\n'\n",
              "                                   '\\n'\n",
              "                                   'While cystic fibrosis (CF) remains '\n",
              "                                   \"Vertex's primary focus, the company has \"\n",
              "                                   'been witnessing rapid success in the '\n",
              "                                   'development of its non-CF pipeline '\n",
              "                                   'candidates. A notable achievement includes '\n",
              "                                   'the approval of Casgevy, a one-shot gene '\n",
              "                                   'therapy developed in partnership with '\n",
              "                                   'CRISPR Therapeutics, for treating sickle '\n",
              "                                   'cell disease and transfusion-dependent '\n",
              "                                   'beta thalassemia in multiple regions in '\n",
              "                                   '2023. These approvals have significantly '\n",
              "                                   \"broadened Vertex's commercial \"\n",
              "                                   'opportunities.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Moreover, Vertex's ambition extends beyond \"\n",
              "                                   'CF and ADPKD. The company is actively '\n",
              "                                   'developing treatments for acute and '\n",
              "                                   'neuropathic pain, APOL1-mediated kidney '\n",
              "                                   'disease, type I diabetes, and alpha-1 '\n",
              "                                   'antitrypsin deficiency, with early-stage '\n",
              "                                   'programs targeting diseases like muscular '\n",
              "                                   'dystrophy. The addition of ADPKD to '\n",
              "                                   'Vertex’s clinical pipeline underscores its '\n",
              "                                   'commitment to tackling a wide range of '\n",
              "                                   'medical challenges, making ADPKD its 10th '\n",
              "                                   'disease area of focus.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"The company's non-CF candidates, \"\n",
              "                                   'particularly in the pain management arena, '\n",
              "                                   'have been drawing significant investor '\n",
              "                                   'interest. VX-548, a novel first-in-class, '\n",
              "                                   'non-opioid NaV1.8 inhibitor, has completed '\n",
              "                                   'three pivotal phase III acute pain '\n",
              "                                   'studies. Announced in January 2024, the '\n",
              "                                   'data revealed that VX-548 significantly '\n",
              "                                   'reduced pain intensity across various '\n",
              "                                   'conditions and settings. Vertex is poised '\n",
              "                                   'to submit a new drug application for '\n",
              "                                   'VX-548 with the FDA for a broad label in '\n",
              "                                   'moderate-to-severe acute pain by mid-2024, '\n",
              "                                   'highlighting its potential as a '\n",
              "                                   'blockbuster drug.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Vertex Pharmaceuticals' relentless pursuit \"\n",
              "                                   'of groundbreaking treatments for complex '\n",
              "                                   'diseases exemplifies its role as a pioneer '\n",
              "                                   'in the pharmaceutical industry. With the '\n",
              "                                   \"FDA's clearance for VX-407's clinical \"\n",
              "                                   'development, Vertex is set to embark on a '\n",
              "                                   'journey that could transform the lives of '\n",
              "                                   'thousands of ADPKD patients. As the '\n",
              "                                   'company continues to expand its clinical '\n",
              "                                   'pipeline and explore new therapeutic '\n",
              "                                   'areas, the future looks promising for '\n",
              "                                   'Vertex and the many patients who stand to '\n",
              "                                   'benefit from its innovative treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Vertex Pharmaceuticals VRTX is up over 35% '\n",
              "                                   'in the past 1 year period. Another biotech '\n",
              "                                   'stock that warrants attention that is up '\n",
              "                                   'over 35% in just 5 days is Actinium '\n",
              "                                   'Pharmaceuticals Inc ATNM. ATNM develops '\n",
              "                                   'targeted radiotherapies to meaningfully '\n",
              "                                   'improve survival for people who have '\n",
              "                                   'failed existing oncology therapies. '\n",
              "                                   'Advanced pipeline candidates Iomab-B '\n",
              "                                   '(pre-BLA & MAA (EU)), an induction and '\n",
              "                                   'conditioning agent prior to bone marrow '\n",
              "                                   'transplant, and Actimab-A (National Cancer '\n",
              "                                   'Institute CRADA pivotal development path), '\n",
              "                                   'a therapeutic agent, have demonstrated '\n",
              "                                   'potential to extend survival outcomes for '\n",
              "                                   'people with relapsed and refractory acute '\n",
              "                                   'myeloid leukemia. Actinium plans to '\n",
              "                                   'advance Iomab-B for other blood cancers '\n",
              "                                   'and next generation conditioning candidate '\n",
              "                                   'Iomab-ACT to improve cell and gene therapy '\n",
              "                                   'outcomes. Actinium holds more than 220 '\n",
              "                                   'patents and patent applications including '\n",
              "                                   'several patents related to the manufacture '\n",
              "                                   'of the isotope Ac-225 in a cyclotron.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Earlier, Maxim raised the firm’s price '\n",
              "                                   'target on Actinium Pharmaceuticals (ATNM) '\n",
              "                                   'to $30 from $20 and kept a Buy rating on '\n",
              "                                   'the shares following another Ac-225 '\n",
              "                                   'acquisition with AstraZeneca AZN to '\n",
              "                                   'acquire Fusion Pharma (FUSN). The firm '\n",
              "                                   'noted that the acquisition comes amidst '\n",
              "                                   'building momentum in the radiopharma '\n",
              "                                   'space, in particular among alpha emitters, '\n",
              "                                   'including the December acquisition of '\n",
              "                                   'RayzeBio (RYZB) by Bristol Meyers BMY for '\n",
              "                                   '$4.1B for its Ac-225 pipeline. Maxim also '\n",
              "                                   'highlights Lilly (LLY) acquiring POINT '\n",
              "                                   'Biopharma in October 2023 for $1.4B, which '\n",
              "                                   'was centered around its pipeline of '\n",
              "                                   'targeted beta – Lu-177 – and alpha – '\n",
              "                                   'Ac-225 – emitting radio-pharmaceuticals. '\n",
              "                                   'The Ac-225 focused M&A activity, which '\n",
              "                                   'given the small number of companies in the '\n",
              "                                   'space, places a potential “scarcity value” '\n",
              "                                   'on Actinium, the firm argues.\\n'\n",
              "                                   '\\n'\n",
              "                                   'In conclusion, as Vertex Pharmaceuticals '\n",
              "                                   'forges ahead with its groundbreaking work '\n",
              "                                   'in treating ADPKD and other significant '\n",
              "                                   'health challenges, the spotlight also '\n",
              "                                   'shines on Actinium Pharmaceuticals '\n",
              "                                   \"((ATNM). The latter's progress and the \"\n",
              "                                   'strategic interest in the '\n",
              "                                   'radiopharmaceutical field highlight an '\n",
              "                                   'exciting era of medical advancements and '\n",
              "                                   'investment opportunities. The future '\n",
              "                                   'indeed looks promising, not just for '\n",
              "                                   'Vertex and Actinium, but for the countless '\n",
              "                                   'patients worldwide who stand to benefit '\n",
              "                                   'from these pioneering therapies\\n'\n",
              "                                   '\\n'\n",
              "                                   'Disclaimer: This blog post is for '\n",
              "                                   'informational purposes only and does not '\n",
              "                                   'constitute financial advice or an '\n",
              "                                   'endorsement of ATNM or its strategies. FOR '\n",
              "                                   'EDUCATIONAL AND INFORMATION PURPOSES ONLY; '\n",
              "                                   'NOT INVESTMENT ADVICE. Please ensure to '\n",
              "                                   'fully read and comprehend our disclaimer '\n",
              "                                   'found at '\n",
              "                                   'https://investorbrandmedia.com/disclaimer/. '\n",
              "                                   'InvestorBrandMedia.com has been '\n",
              "                                   'compensated a total of three thousand '\n",
              "                                   'dollars by a 3rd party Bullzeyemedia LLC '\n",
              "                                   'for content distribution services on ATNM '\n",
              "                                   'from March 20th to March 25th, 2024. We '\n",
              "                                   'own zero shares of ATNM. '\n",
              "                                   'InvestorBrandMedia.com is neither an '\n",
              "                                   'investment advisor nor a registered '\n",
              "                                   'broker. No current owner, employee, or '\n",
              "                                   'independent contractor of '\n",
              "                                   'InvestorBrandMedia.com is registered as a '\n",
              "                                   'securities broker-dealer, broker, '\n",
              "                                   'investment advisor, or IA representative '\n",
              "                                   'with the U.S. Securities and Exchange '\n",
              "                                   'Commission, any state securities '\n",
              "                                   'regulatory authority, or any '\n",
              "                                   'self-regulatory organization. This article '\n",
              "                                   'may contain forward-looking statements as '\n",
              "                                   'defined under Section 27A of the '\n",
              "                                   'Securities Act of 1933 and 21E of the '\n",
              "                                   'Exchange Act of 1934. These statements, '\n",
              "                                   'often incorporating terms like “believes,” '\n",
              "                                   '“anticipates,” “estimates,” “expects,” '\n",
              "                                   '“projects,” “intends,” or similar '\n",
              "                                   'expressions about future performance or '\n",
              "                                   'conduct, are based on present '\n",
              "                                   'expectations, estimates, and projections, '\n",
              "                                   'and are not historical facts. They carry '\n",
              "                                   'various risks and uncertainties that may '\n",
              "                                   'result in significant deviation from the '\n",
              "                                   'anticipated results or events. Past '\n",
              "                                   'performance does not guarantee future '\n",
              "                                   'results.InvestorBrandMedia.com does not '\n",
              "                                   'commit to updating forward-looking '\n",
              "                                   'statements based on new information or '\n",
              "                                   'future events. Readers are encouraged to '\n",
              "                                   'review all public SEC filings made by the '\n",
              "                                   'profiled companies at '\n",
              "                                   'https://www.sec.gov/edgar/searchedgar/companysearch. '\n",
              "                                   'It is always important to conduct thorough '\n",
              "                                   'due diligence and exercise caution in '\n",
              "                                   'trading.InvestorBrandMedia.com is not '\n",
              "                                   'managed by a licensed broker, a dealer, or '\n",
              "                                   'a registered investment adviser. The '\n",
              "                                   'content here is purely informational and '\n",
              "                                   'should not be taken as investment advice. '\n",
              "                                   'The Private Securities Litigation Reform '\n",
              "                                   'Act of 1995 provides investors a safe '\n",
              "                                   'harbor regarding forward-looking '\n",
              "                                   'statements. Any statement that projects, '\n",
              "                                   'foresees, expects, anticipates, estimates, '\n",
              "                                   'believes, or understands certain actions '\n",
              "                                   'to possibly occur are not historical facts '\n",
              "                                   'and may be forward-looking statements. '\n",
              "                                   'These statements are based on '\n",
              "                                   'expectations, estimates, and projections '\n",
              "                                   'that could cause actual results to differ '\n",
              "                                   'greatly from those anticipated. Investing '\n",
              "                                   'in micro-cap and growth securities is '\n",
              "                                   'speculative and entails a high degree of '\n",
              "                                   'risk, potentially leading to a total or '\n",
              "                                   'substantial loss of investment. Please '\n",
              "                                   'note that no content published here '\n",
              "                                   'constitutes a recommendation to buy or '\n",
              "                                   'sell a security. It is solely '\n",
              "                                   'informational, and you should not construe '\n",
              "                                   'it as legal, tax, investment, financial, '\n",
              "                                   'or other advice. No content in this '\n",
              "                                   'article constitutes an offer or '\n",
              "                                   'solicitation by InvestorBrandMedia.com or '\n",
              "                                   'any third-party service provider to buy or '\n",
              "                                   'sell securities or other financial '\n",
              "                                   'instruments. The content in this article '\n",
              "                                   'does not address the circumstances of any '\n",
              "                                   'specific individual or entity and does not '\n",
              "                                   'constitute professional and/or financial '\n",
              "                                   'advice. InvestorBrandMedia.com is not a '\n",
              "                                   'fiduciary by virtue of any person’s use of '\n",
              "                                   'or access to this content.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Source: '\n",
              "                                   'https://finance.yahoo.com/quote/ATNM/\\n'\n",
              "                                   '\\n'\n",
              "                                   'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://www.tipranks.com/news/the-fly/actinium-pharmaceuticals-price-target-raised-to-30-from-20-at-maxim\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://seekingalpha.com/news/4081208-actinium-stock-spikes-astra-fusion-deal\\n'\n",
              "                                   '\\n'\n",
              "                                   'Source: '\n",
              "                                   'https://www.cnbc.com/2024/03/21/retail-traders-are-bailing-on-3-of-the-hottest-ai-plays-in-the-market-today.html\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/industry/biotechnology\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/news/vertex-vrtx-kidney-disease-drug-160900770.html\\n'\n",
              "                                   '\\n'\n",
              "                                   'Media Contact\\n'\n",
              "                                   '\\n'\n",
              "                                   'Company Name: Investor Brand Media\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact Person: Ash K\\n'\n",
              "                                   '\\n'\n",
              "                                   'Email: investorbrandmedia@gmail.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'Phone: (954) 593-5597\\n'\n",
              "                                   '\\n'\n",
              "                                   'Country: United States\\n'\n",
              "                                   '\\n'\n",
              "                                   'Website: https://investorbrandmedia.com/\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   'Press Release Distributed by '\n",
              "                                   'ABNewswire.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'To view the original version on ABNewswire '\n",
              "                                   'visit: FDA Approves Vertex Pharmaceuticals '\n",
              "                                   'VRTX VX-407 for Phase I Study in '\n",
              "                                   'Groundbreaking Move Against Polycystic '\n",
              "                                   'Kidney Disease\\\\\"'},\n",
              "              'score': 0.823967,\n",
              "              'values': []},\n",
              "             {'id': '1220',\n",
              "              'metadata': {'text': 'Acquisition Marks AstraZeneca’s Commitment '\n",
              "                                   'to Advancing Cancer Care with '\n",
              "                                   'Radioconjugates\\n'\n",
              "                                   '\\n'\n",
              "                                   'AstraZeneca, (AZN) a leading global '\n",
              "                                   'biopharmaceutical company, has announced a '\n",
              "                                   'definitive agreement to acquire Fusion '\n",
              "                                   'Pharmaceuticals Inc., (FUSN) a '\n",
              "                                   'clinical-stage oncology company renowned '\n",
              "                                   'for its development of next-generation '\n",
              "                                   'radioconjugates as precision medicines. '\n",
              "                                   'This strategic move underscores '\n",
              "                                   'AstraZeneca’s dedication to '\n",
              "                                   'revolutionizing cancer treatment and '\n",
              "                                   'outcomes by replacing conventional '\n",
              "                                   'regimens like chemotherapy and '\n",
              "                                   'radiotherapy with more targeted '\n",
              "                                   'therapies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Radioconjugates (RCs) have emerged as a '\n",
              "                                   'promising modality in cancer treatment, '\n",
              "                                   'offering the potential to deliver '\n",
              "                                   'radioactive isotopes directly to cancer '\n",
              "                                   'cells with precision. Fusion’s innovative '\n",
              "                                   'approach utilizes molecules such as '\n",
              "                                   'antibodies, peptides, or small molecules '\n",
              "                                   'to precisely target cancer cells, '\n",
              "                                   'minimizing damage to healthy tissue and '\n",
              "                                   'expanding the reach of treatment to tumors '\n",
              "                                   'previously inaccessible through '\n",
              "                                   'traditional methods.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The acquisition will augment AstraZeneca’s '\n",
              "                                   'leading oncology portfolio with Fusion’s '\n",
              "                                   'pipeline of RCs, including its advanced '\n",
              "                                   'program FPI-2265, designed to address '\n",
              "                                   'metastatic castration-resistant prostate '\n",
              "                                   'cancer (mCRPC). FPI-2265 targets '\n",
              "                                   'prostate-specific membrane antigen (PSMA), '\n",
              "                                   'a protein highly expressed in mCRPC, and '\n",
              "                                   'is currently undergoing Phase 2 trials.\\n'\n",
              "                                   '\\n'\n",
              "                                   'With this acquisition, AstraZeneca gains '\n",
              "                                   'access to Fusion’s expertise in '\n",
              "                                   'radioconjugates, including pioneering '\n",
              "                                   'research and development, manufacturing '\n",
              "                                   'capabilities, and the supply chain for '\n",
              "                                   'actinium-based RCs. This strategic '\n",
              "                                   'collaboration reinforces AstraZeneca’s '\n",
              "                                   'commitment to advancing cancer care and '\n",
              "                                   'underscores its position as a leader in '\n",
              "                                   'the oncology space.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The transaction, valued at approximately '\n",
              "                                   '$2 billion, represents a significant '\n",
              "                                   'premium to Fusion’s market price and '\n",
              "                                   'underscores AstraZeneca’s confidence in '\n",
              "                                   'Fusion’s innovative approach to cancer '\n",
              "                                   'therapy. The acquisition is expected to '\n",
              "                                   'close in the second quarter of 2024, '\n",
              "                                   'subject to regulatory approvals and '\n",
              "                                   'customary closing conditions, marking a '\n",
              "                                   'milestone in the journey towards '\n",
              "                                   'transformative cancer treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Read the original press release: here'},\n",
              "              'score': 0.768089533,\n",
              "              'values': []},\n",
              "             {'id': '23',\n",
              "              'metadata': {'text': 'Transaction includes actinium-based '\n",
              "                                   'clinical-stage radioconjugate targeting '\n",
              "                                   'PSMA for prostate cancer, pipeline of '\n",
              "                                   'radioconjugates and state-of-the-art R&D '\n",
              "                                   'and manufacturing facilities\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion shareholders to receive $21.00 per '\n",
              "                                   'share in cash at closing plus a '\n",
              "                                   'non-transferrable contingent value right '\n",
              "                                   '(CVR) of $3.00 per share, representing a '\n",
              "                                   'total transaction value of approximately '\n",
              "                                   '$2.4 billion including the CVR\\n'\n",
              "                                   '\\n'\n",
              "                                   'HAMILTON, ON and BOSTON, March 19, 2024 '\n",
              "                                   '/PRNewswire/ -- Fusion Pharmaceuticals '\n",
              "                                   'Inc. (Nasdaq: FUSN), a clinical-stage '\n",
              "                                   'oncology company focused on developing '\n",
              "                                   'next-generation radioconjugates (RCs) as '\n",
              "                                   'precision medicines, today announced the '\n",
              "                                   'Company has entered into a definitive '\n",
              "                                   'agreement to be acquired by AstraZeneca. '\n",
              "                                   'The acquisition marks a major step forward '\n",
              "                                   'in AstraZeneca delivering on its ambition '\n",
              "                                   'to transform cancer treatment and outcomes '\n",
              "                                   'for patients by replacing traditional '\n",
              "                                   'regimens like chemotherapy and '\n",
              "                                   'radiotherapy with more targeted '\n",
              "                                   'treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs have emerged as a promising modality '\n",
              "                                   'in cancer treatment over recent years. '\n",
              "                                   'These medicines deliver a radioactive '\n",
              "                                   'isotope directly to cancer cells through '\n",
              "                                   'precise targeting using molecules such as '\n",
              "                                   'antibodies, peptides or small molecules. '\n",
              "                                   'This approach has many potential '\n",
              "                                   'advantages compared to traditional '\n",
              "                                   'radiotherapy, including minimizing damage '\n",
              "                                   'to healthy cells and enabling access to '\n",
              "                                   'tumors not reachable through external beam '\n",
              "                                   'radiation.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"This acquisition complements AstraZeneca's \"\n",
              "                                   'leading oncology portfolio with the '\n",
              "                                   'addition of the Fusion pipeline of RCs, '\n",
              "                                   \"including the Company's most advanced \"\n",
              "                                   'program, FPI-2265, a potential new '\n",
              "                                   'treatment for patients with metastatic '\n",
              "                                   'castration-resistant prostate cancer '\n",
              "                                   '(mCRPC). FPI-2265 targets '\n",
              "                                   'prostate-specific membrane antigen (PSMA), '\n",
              "                                   'a protein that is highly expressed in '\n",
              "                                   'mCRPC, and is currently in a Phase 2 '\n",
              "                                   'trial.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The acquisition brings new expertise and '\n",
              "                                   'pioneering R&D, manufacturing and supply '\n",
              "                                   'chain capabilities in actinium-based RCs '\n",
              "                                   'to AstraZeneca. It also strengthens their '\n",
              "                                   'presence in and commitment to Canada.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Chief Executive Officer John '\n",
              "                                   'Valliant, Ph.D., said: \"This acquisition '\n",
              "                                   \"combines Fusion's expertise and \"\n",
              "                                   'capabilities in radioconjugates, including '\n",
              "                                   'our industry-leading radiopharmaceutical '\n",
              "                                   'R&D, pipeline, manufacturing and '\n",
              "                                   'actinium-225 supply chain, with '\n",
              "                                   \"AstraZeneca's leadership in small \"\n",
              "                                   'molecules and biologics engineering to '\n",
              "                                   'develop novel radioconjugates. Expanding '\n",
              "                                   'on our existing collaboration with '\n",
              "                                   'AstraZeneca where we have advanced '\n",
              "                                   'FPI-2068, an EGFR-cMET targeted '\n",
              "                                   'radioconjugate into Phase I clinical '\n",
              "                                   'trials, gives us a unique opportunity to '\n",
              "                                   'accelerate the development of '\n",
              "                                   'next-generation radioconjugates with the '\n",
              "                                   'aim of transforming patient outcomes.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Susan Galbraith, Executive Vice President, '\n",
              "                                   'Oncology R&D, AstraZeneca, said: \"Between '\n",
              "                                   'thirty and fifty per cent of patients with '\n",
              "                                   'cancer today receive radiotherapy at some '\n",
              "                                   'point during treatment, and the '\n",
              "                                   'acquisition of Fusion furthers our '\n",
              "                                   'ambition to transform this aspect of care '\n",
              "                                   'with next-generation radioconjugates. '\n",
              "                                   'Together with Fusion, we have an '\n",
              "                                   'opportunity to accelerate the development '\n",
              "                                   'of FPI-2265 as a potential new treatment '\n",
              "                                   'for prostate cancer, and to harness their '\n",
              "                                   'innovative actinium-based platform to '\n",
              "                                   'develop radioconjugates as foundational '\n",
              "                                   'regimens.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion President and Chief Business '\n",
              "                                   'Officer Mohit Rawat, said: \"Fusion has '\n",
              "                                   'differentiated itself in the growing '\n",
              "                                   'radioconjugate space by assembling an '\n",
              "                                   'industry-leading team with deep expertise '\n",
              "                                   'and infrastructure to support bringing '\n",
              "                                   'these much-needed therapies to cancer '\n",
              "                                   'patients. Together we look forward to '\n",
              "                                   'building upon our work to impact the '\n",
              "                                   'landscape of cancer therapy. Deepening our '\n",
              "                                   'collaboration with AstraZeneca presents an '\n",
              "                                   'exciting opportunity for the Fusion '\n",
              "                                   'team.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion will become a wholly owned '\n",
              "                                   'subsidiary of AstraZeneca, with operations '\n",
              "                                   'continuing in Canada and the US.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Financial Considerations\\n'\n",
              "                                   '\\n'\n",
              "                                   'Under the terms of the definitive '\n",
              "                                   'agreement, AstraZeneca, through a '\n",
              "                                   \"subsidiary, will acquire all of Fusion's \"\n",
              "                                   'outstanding shares pursuant to a plan of '\n",
              "                                   'arrangement for a price of $21.00 per '\n",
              "                                   'share in cash at closing plus a '\n",
              "                                   'non-transferable contingent value right '\n",
              "                                   '(CVR) of $3.00 per share in cash payable '\n",
              "                                   'upon the achievement of a specified '\n",
              "                                   'regulatory milestone.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The upfront cash portion of the '\n",
              "                                   'consideration represents a transaction '\n",
              "                                   'value of approximately $2 billion, a 97% '\n",
              "                                   \"premium to Fusion's closing market price \"\n",
              "                                   'of $10.64 on March 18, 2024, and an 85% '\n",
              "                                   'premium to the 30-day volume-weighted '\n",
              "                                   'average price (VWAP) of $11.37 before this '\n",
              "                                   'announcement. Combined, the upfront and '\n",
              "                                   'maximum potential contingent value '\n",
              "                                   'payments represent, if achieved, a '\n",
              "                                   'transaction value of approximately $2.4 '\n",
              "                                   \"billion, a 126% premium to Fusion's \"\n",
              "                                   'closing market price on March 18, 2024, '\n",
              "                                   'and a 111% premium to the 30-day VWAP. As '\n",
              "                                   'part of the transaction, AstraZeneca will '\n",
              "                                   'acquire the cash, cash equivalents and '\n",
              "                                   \"short-term investments on Fusion's balance \"\n",
              "                                   'sheet, which totaled $234 million as of '\n",
              "                                   'December 31, 2023.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The proposed acquisition of Fusion is to '\n",
              "                                   'be completed by way of a statutory plan of '\n",
              "                                   'arrangement under the Canada Business '\n",
              "                                   'Corporations Act and subject to customary '\n",
              "                                   'closing conditions, including approval of '\n",
              "                                   '(i) 66⅔% of the votes cast by Fusion '\n",
              "                                   'shareholders and (ii) a simple majority of '\n",
              "                                   'the votes cast by Fusion shareholders '\n",
              "                                   '(excluding certain persons required to be '\n",
              "                                   'excluded in accordance with Multilateral '\n",
              "                                   'Instrument 61-101 of the Canadian '\n",
              "                                   'Securities Administrators), in each case, '\n",
              "                                   'at a special meeting of Fusion '\n",
              "                                   'shareholders. The transaction is expected '\n",
              "                                   'to close in the second quarter of 2024, '\n",
              "                                   'subject to customary closing conditions, '\n",
              "                                   'including the approval of Fusion '\n",
              "                                   'shareholders and regulatory clearances, as '\n",
              "                                   'noted above.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Centerview Partners LLC is serving as '\n",
              "                                   'exclusive financial advisor to Fusion and '\n",
              "                                   'Goodwin Procter LLP is serving as legal '\n",
              "                                   'counsel, with Osler, Hoskin & Harcourt LLP '\n",
              "                                   'serving as Canadian legal counsel.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Radioconjugates in oncology\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs combine the precise targeting of '\n",
              "                                   'antibodies, small molecules or peptides '\n",
              "                                   'with potent medical radioisotopes to '\n",
              "                                   'deliver radiation directly to cancer '\n",
              "                                   'cells. By seeking out cancer cells, RCs '\n",
              "                                   'provide a more precise mechanism of cancer '\n",
              "                                   'cell killing compared with traditional '\n",
              "                                   'radiation therapy, with the goal of '\n",
              "                                   'improving efficacy while minimizing '\n",
              "                                   'toxicity on healthy cells. RCs are '\n",
              "                                   'administered via systemic delivery, which '\n",
              "                                   'enables their use in tumor types not '\n",
              "                                   'accessible to external beam radiation and '\n",
              "                                   'the targeting of cancer cells that have '\n",
              "                                   'spread from the main tumor to other sites '\n",
              "                                   'in the body.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About FPI-2265\\n'\n",
              "                                   '\\n'\n",
              "                                   'FPI-2265 is an actinium-225 based PSMA '\n",
              "                                   'targeting RC, for mCRPC, currently in a '\n",
              "                                   'Phase II trial. Actinium-225 emits alpha '\n",
              "                                   'particles and holds the promise of being a '\n",
              "                                   'next-generation radioisotope in cancer '\n",
              "                                   'treatment. By delivering a greater '\n",
              "                                   'radiation dose over a shorter distance, '\n",
              "                                   'alpha particles such as actinium-225 have '\n",
              "                                   'the potential for more potent cancer cell '\n",
              "                                   'killing, and targeted delivery, thereby '\n",
              "                                   'minimizing damage to surrounding healthy '\n",
              "                                   'tissue.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About Fusion\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Pharmaceuticals is a clinical-stage '\n",
              "                                   'oncology company focused on developing '\n",
              "                                   'next-generation RCs. Fusion connects alpha '\n",
              "                                   'particle emitting isotopes to various '\n",
              "                                   'targeting molecules in order to '\n",
              "                                   'selectively deliver the alpha emitting '\n",
              "                                   \"payloads to tumors. Fusion's \"\n",
              "                                   'clinical-stage development portfolio '\n",
              "                                   'includes lead program, FPI-2265, targeting '\n",
              "                                   'PSMA for mCRPC and novel RCs targeting '\n",
              "                                   'solid tumors.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cautionary Note Regarding Forward-Looking '\n",
              "                                   'Statements\\n'\n",
              "                                   '\\n'\n",
              "                                   'To the extent any statements made in this '\n",
              "                                   'communication contain information that is '\n",
              "                                   'not historical, these statements are '\n",
              "                                   'forward-looking statements within the '\n",
              "                                   'meaning of Section 27A of the U.S. '\n",
              "                                   'Securities Act of 1933, as amended, and '\n",
              "                                   'Section 21E of the U.S. Securities '\n",
              "                                   'Exchange Act of 1934, as amended, and '\n",
              "                                   'forward-looking information under Canadian '\n",
              "                                   'securities law (collectively, '\n",
              "                                   '\"forward-looking statements\"). Certain '\n",
              "                                   'statements in this communication may '\n",
              "                                   'constitute forward-looking statements, '\n",
              "                                   \"which reflect the expectations of Fusion's \"\n",
              "                                   'management regarding the business '\n",
              "                                   'prospects and opportunities of Fusion and '\n",
              "                                   'the proposed transaction. The use of words '\n",
              "                                   'such as \"may,\" \"will,\" \"could,\" \"should,\" '\n",
              "                                   '\"expects,\" \"intends,\" \"plans,\" '\n",
              "                                   '\"anticipates,\" \"believes,\" \"estimates,\" '\n",
              "                                   '\"predicts,\" \"projects,\" \"seeks,\" '\n",
              "                                   '\"endeavor,\" \"potential,\" \"continue\" or the '\n",
              "                                   'negative of such words or other similar '\n",
              "                                   'expressions can be used to identify '\n",
              "                                   'forward-looking statements. More '\n",
              "                                   'particularly and without limitation, this '\n",
              "                                   'communication contains forward-looking '\n",
              "                                   'statements and information regarding '\n",
              "                                   'whether the proposed transaction will be '\n",
              "                                   'completed, whether the CVR Agreement will '\n",
              "                                   'be entered into, the anticipated benefits '\n",
              "                                   'of the proposed transaction for Fusion and '\n",
              "                                   'its Shareholders, whether approval will be '\n",
              "                                   'received under the U.S. Hart-Scott-Rodino '\n",
              "                                   'Antitrust Improvements Act of 1976 and the '\n",
              "                                   'Competition Act (Canada), each as amended, '\n",
              "                                   'and whether the milestone under the CVR '\n",
              "                                   'Agreement will be achieved.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Fusion's actual results could differ \"\n",
              "                                   'materially from those stated or implied in '\n",
              "                                   'forward-looking statements due to a number '\n",
              "                                   'of factors including but not limited to '\n",
              "                                   'risks related to the satisfaction or '\n",
              "                                   'waiver of the conditions to closing the '\n",
              "                                   'proposed transaction (including the '\n",
              "                                   'failure to obtain necessary regulatory, '\n",
              "                                   \"court and Fusion's shareholder approvals) \"\n",
              "                                   'in the anticipated timeframe or at all, '\n",
              "                                   'including the possibility that the '\n",
              "                                   'proposed transaction does not close; the '\n",
              "                                   'response of business partners and '\n",
              "                                   'competitors to the announcement of the '\n",
              "                                   'proposed transaction, and/or potential '\n",
              "                                   'difficulties in employee retention as a '\n",
              "                                   'result of the announcement and pendency of '\n",
              "                                   'the proposed transaction; significant '\n",
              "                                   'transaction costs; the failure to realize '\n",
              "                                   'the expected benefits of the proposed '\n",
              "                                   'transaction; risks associated with the '\n",
              "                                   \"disruption of management's attention from \"\n",
              "                                   'ongoing business operations due to the '\n",
              "                                   'proposed transaction; and unknown '\n",
              "                                   'liabilities and the risk of litigation '\n",
              "                                   'and/or regulatory actions related to the '\n",
              "                                   'proposed transaction. Please also refer to '\n",
              "                                   'the factors discussed under \"Risk Factors\" '\n",
              "                                   'and \"Special Note Regarding '\n",
              "                                   'Forward-looking Information\" in Fusion\\'s '\n",
              "                                   'Annual Report on Form 10-K for the year '\n",
              "                                   'ended December 31, 2022, with the U.S. '\n",
              "                                   'Securities Exchange Commission (\"SEC\"), '\n",
              "                                   \"each as updated by Fusion's continuous \"\n",
              "                                   'disclosure filings, which are available at '\n",
              "                                   'www.sec.gov and at www.sedarplus.com.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Forward-looking statements involve '\n",
              "                                   'significant risks and uncertainties, '\n",
              "                                   'should not be read as guarantees of future '\n",
              "                                   'performance or results, and will not '\n",
              "                                   'necessarily be accurate indications of '\n",
              "                                   'whether or not or the times at or by which '\n",
              "                                   'such performance or results will be '\n",
              "                                   'achieved. All forward-looking statements '\n",
              "                                   'herein are qualified in their entirety by '\n",
              "                                   'its cautionary statement and are made as '\n",
              "                                   'of the date of this document. Fusion '\n",
              "                                   'disclaims any obligation to revise or '\n",
              "                                   'update any such forward-looking statements '\n",
              "                                   'or to publicly announce the result of any '\n",
              "                                   'revisions to any of the forward-looking '\n",
              "                                   'statements contained herein to reflect '\n",
              "                                   'future results, events or developments, '\n",
              "                                   'except as required by law.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Additional Information about the Proposed '\n",
              "                                   'Transaction and Where to Find It\\n'\n",
              "                                   '\\n'\n",
              "                                   'This communication is not intended to and '\n",
              "                                   'does not constitute an offer to sell or '\n",
              "                                   'the solicitation of an offer to subscribe '\n",
              "                                   'for or buy or an invitation to purchase or '\n",
              "                                   'subscribe for any securities or the '\n",
              "                                   'solicitation of any vote, consent or '\n",
              "                                   'approval in any jurisdiction, nor shall '\n",
              "                                   'there by any sale, issuance or transfer of '\n",
              "                                   'securities in any jurisdiction in '\n",
              "                                   'contravention of applicable law. This '\n",
              "                                   'communication has been prepared in respect '\n",
              "                                   'of the transaction involving Fusion, '\n",
              "                                   'AstraZeneca and Purchaser (as defined in '\n",
              "                                   'the Arrangement Agreement) pursuant to the '\n",
              "                                   'terms of the Arrangement Agreement, and '\n",
              "                                   'may be deemed to be soliciting material '\n",
              "                                   'relating to the transaction. In connection '\n",
              "                                   'with the transaction, Fusion will file a '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement on Schedule 14A relating to a '\n",
              "                                   'special meeting of the shareholders with '\n",
              "                                   'the SEC and Canadian Securities '\n",
              "                                   'Administrators (\"CSA\"). Additionally, '\n",
              "                                   'Fusion will file other relevant materials '\n",
              "                                   'in connection with the transaction with '\n",
              "                                   'the SEC and the CSA. Shareholders of '\n",
              "                                   'Fusion are urged to read the management '\n",
              "                                   'information circular and proxy statement '\n",
              "                                   'and/or consent solicitation documents '\n",
              "                                   'regarding the transaction and any other '\n",
              "                                   'relevant materials carefully in their '\n",
              "                                   'entirety when they become available before '\n",
              "                                   'making any voting or investment decision '\n",
              "                                   'with respect to the transaction because '\n",
              "                                   'they will contain important information '\n",
              "                                   'about the transaction and the parties to '\n",
              "                                   'the Arrangement Agreement. The definitive '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement will be mailed to holders of '\n",
              "                                   \"Fusion's shares. Shareholders will be able \"\n",
              "                                   'to obtain a copy of the management '\n",
              "                                   'information circular and proxy statement, '\n",
              "                                   'as well as other filings containing '\n",
              "                                   'information about the transaction and the '\n",
              "                                   'parties to the Arrangement Agreement made '\n",
              "                                   'by Fusion with the SEC and CSA free of '\n",
              "                                   'charge on EDGAR at www.sec.gov , on SEDAR+ '\n",
              "                                   \"at www.sedarplus.com , or on Fusion's \"\n",
              "                                   'website at www.fusionpharma.com . '\n",
              "                                   'Information contained on, or that may be '\n",
              "                                   'accessed through, the websites referenced '\n",
              "                                   'in this communication is not incorporated '\n",
              "                                   'into and does not constitute a part of '\n",
              "                                   'this document. We have included these '\n",
              "                                   'website addresses only as inactive textual '\n",
              "                                   'references and do not intend them to be '\n",
              "                                   'active links.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Participants in the Solicitation\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion and its directors and executive '\n",
              "                                   'officers may be deemed to be participants '\n",
              "                                   'in the solicitation of proxies from the '\n",
              "                                   'shareholders of Fusion in respect of the '\n",
              "                                   \"transaction. Information about Fusion's \"\n",
              "                                   'directors and executive officers is set '\n",
              "                                   'forth in the proxy statement and '\n",
              "                                   'management information circular for '\n",
              "                                   \"Fusion's Annual General Meeting of \"\n",
              "                                   'Shareholders, which was filed with the SEC '\n",
              "                                   'and CSA on April 27, 2023. Investors may '\n",
              "                                   'obtain additional information regarding '\n",
              "                                   'the interest of such participants by '\n",
              "                                   'reading the management information '\n",
              "                                   'circular and proxy statement regarding the '\n",
              "                                   'proposed transaction when it becomes '\n",
              "                                   'available.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact:\\n'\n",
              "                                   '\\n'\n",
              "                                   'Amanda Cray\\n'\n",
              "                                   '\\n'\n",
              "                                   'Senior Director of Investor Relations & '\n",
              "                                   'Corporate Communications\\n'\n",
              "                                   '\\n'\n",
              "                                   '(617) 967-0207\\n'\n",
              "                                   '\\n'\n",
              "                                   '[email protected]\\n'\n",
              "                                   '\\n'\n",
              "                                   'SOURCE Fusion Pharmaceuticals'},\n",
              "              'score': 0.767369688,\n",
              "              'values': []},\n",
              "             {'id': '772',\n",
              "              'metadata': {'text': 'Fusion Pharmaceuticals to be Acquired by '\n",
              "                                   'AstraZeneca, Accelerating Development of '\n",
              "                                   'Next-Generation Radioconjugates to Treat '\n",
              "                                   'Cancer\\n'\n",
              "                                   '\\n'\n",
              "                                   'Transaction includes actinium-based '\n",
              "                                   'clinical-stage radioconjugate targeting '\n",
              "                                   'PSMA for prostate cancer, pipeline of '\n",
              "                                   'radioconjugates and state-of-the-art R&D '\n",
              "                                   'and manufacturing facilities\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion shareholders to receive $21.00 per '\n",
              "                                   'share in cash at closing plus a '\n",
              "                                   'non-transferrable contingent value right '\n",
              "                                   '(CVR) of $3.00 per share, representing a '\n",
              "                                   'total transaction value of approximately '\n",
              "                                   '$2.4 billion including the CVR\\n'\n",
              "                                   '\\n'\n",
              "                                   'HAMILTON, ON and BOSTON, March 19, 2024 '\n",
              "                                   '/PRNewswire/ -- Fusion Pharmaceuticals '\n",
              "                                   'Inc. (Nasdaq: FUSN), a clinical-stage '\n",
              "                                   'oncology company focused on developing '\n",
              "                                   'next-generation radioconjugates (RCs) as '\n",
              "                                   'precision medicines, today announced the '\n",
              "                                   'Company has entered into a definitive '\n",
              "                                   'agreement to be acquired by AstraZeneca. '\n",
              "                                   'The acquisition marks a major step forward '\n",
              "                                   'in AstraZeneca delivering on its ambition '\n",
              "                                   'to transform cancer treatment and outcomes '\n",
              "                                   'for patients by replacing traditional '\n",
              "                                   'regimens like chemotherapy and '\n",
              "                                   'radiotherapy with more targeted '\n",
              "                                   'treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs have emerged as a promising modality '\n",
              "                                   'in cancer treatment over recent years. '\n",
              "                                   'These medicines deliver a radioactive '\n",
              "                                   'isotope directly to cancer cells through '\n",
              "                                   'precise targeting using molecules such as '\n",
              "                                   'antibodies, peptides or small molecules. '\n",
              "                                   'This approach has many potential '\n",
              "                                   'advantages compared to traditional '\n",
              "                                   'radiotherapy, including minimizing damage '\n",
              "                                   'to healthy cells and enabling access to '\n",
              "                                   'tumors not reachable through external beam '\n",
              "                                   'radiation.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"This acquisition complements AstraZeneca's \"\n",
              "                                   'leading oncology portfolio with the '\n",
              "                                   'addition of the Fusion pipeline of RCs, '\n",
              "                                   \"including the Company's most advanced \"\n",
              "                                   'program, FPI-2265, a potential new '\n",
              "                                   'treatment for patients with metastatic '\n",
              "                                   'castration-resistant prostate cancer '\n",
              "                                   '(mCRPC). FPI-2265 targets '\n",
              "                                   'prostate-specific membrane antigen (PSMA), '\n",
              "                                   'a protein that is highly expressed in '\n",
              "                                   'mCRPC, and is currently in a Phase 2 '\n",
              "                                   'trial.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The acquisition brings new expertise and '\n",
              "                                   'pioneering R&D, manufacturing and supply '\n",
              "                                   'chain capabilities in actinium-based RCs '\n",
              "                                   'to AstraZeneca. It also strengthens their '\n",
              "                                   'presence in and commitment to Canada.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Chief Executive Officer John '\n",
              "                                   'Valliant, Ph.D., said: \"This acquisition '\n",
              "                                   \"combines Fusion's expertise and \"\n",
              "                                   'capabilities in radioconjugates, including '\n",
              "                                   'our industry-leading radiopharmaceutical '\n",
              "                                   'R&D, pipeline, manufacturing and '\n",
              "                                   'actinium-225 supply chain, with '\n",
              "                                   \"AstraZeneca's leadership in small \"\n",
              "                                   'molecules and biologics engineering to '\n",
              "                                   'develop novel radioconjugates. Expanding '\n",
              "                                   'on our existing collaboration with '\n",
              "                                   'AstraZeneca where we have advanced '\n",
              "                                   'FPI-2068, an EGFR-cMET targeted '\n",
              "                                   'radioconjugate into Phase I clinical '\n",
              "                                   'trials, gives us a unique opportunity to '\n",
              "                                   'accelerate the development of '\n",
              "                                   'next-generation radioconjugates with the '\n",
              "                                   'aim of transforming patient outcomes.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Susan Galbraith, Executive Vice President, '\n",
              "                                   'Oncology R&D, AstraZeneca, said: \"Between '\n",
              "                                   'thirty and fifty per cent of patients with '\n",
              "                                   'cancer today receive radiotherapy at some '\n",
              "                                   'point during treatment, and the '\n",
              "                                   'acquisition of Fusion furthers our '\n",
              "                                   'ambition to transform this aspect of care '\n",
              "                                   'with next-generation radioconjugates. '\n",
              "                                   'Together with Fusion, we have an '\n",
              "                                   'opportunity to accelerate the development '\n",
              "                                   'of FPI-2265 as a potential new treatment '\n",
              "                                   'for prostate cancer, and to harness their '\n",
              "                                   'innovative actinium-based platform to '\n",
              "                                   'develop radioconjugates as foundational '\n",
              "                                   'regimens.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion President and Chief Business '\n",
              "                                   'Officer Mohit Rawat, said: \"Fusion has '\n",
              "                                   'differentiated itself in the growing '\n",
              "                                   'radioconjugate space by assembling an '\n",
              "                                   'industry-leading team with deep expertise '\n",
              "                                   'and infrastructure to support bringing '\n",
              "                                   'these much-needed therapies to cancer '\n",
              "                                   'patients. Together we look forward to '\n",
              "                                   'building upon our work to impact the '\n",
              "                                   'landscape of cancer therapy. Deepening our '\n",
              "                                   'collaboration with AstraZeneca presents an '\n",
              "                                   'exciting opportunity for the Fusion '\n",
              "                                   'team.\"\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion will become a wholly owned '\n",
              "                                   'subsidiary of AstraZeneca, with operations '\n",
              "                                   'continuing in Canada and the US.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Financial Considerations\\n'\n",
              "                                   '\\n'\n",
              "                                   'Under the terms of the definitive '\n",
              "                                   'agreement, AstraZeneca, through a '\n",
              "                                   \"subsidiary, will acquire all of Fusion's \"\n",
              "                                   'outstanding shares pursuant to a plan of '\n",
              "                                   'arrangement for a price of $21.00 per '\n",
              "                                   'share in cash at closing plus a '\n",
              "                                   'non-transferable contingent value right '\n",
              "                                   '(CVR) of $3.00 per share in cash payable '\n",
              "                                   'upon the achievement of a specified '\n",
              "                                   'regulatory milestone.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The upfront cash portion of the '\n",
              "                                   'consideration represents a transaction '\n",
              "                                   'value of approximately $2 billion, a 97% '\n",
              "                                   \"premium to Fusion's closing market price \"\n",
              "                                   'of $10.64 on March 18, 2024, and an 85% '\n",
              "                                   'premium to the 30-day volume-weighted '\n",
              "                                   'average price (VWAP) of $11.37 before this '\n",
              "                                   'announcement. Combined, the upfront and '\n",
              "                                   'maximum potential contingent value '\n",
              "                                   'payments represent, if achieved, a '\n",
              "                                   'transaction value of approximately $2.4 '\n",
              "                                   \"billion, a 126% premium to Fusion's \"\n",
              "                                   'closing market price on March 18, 2024, '\n",
              "                                   'and a 111% premium to the 30-day VWAP. As '\n",
              "                                   'part of the transaction, AstraZeneca will '\n",
              "                                   'acquire the cash, cash equivalents and '\n",
              "                                   \"short-term investments on Fusion's balance \"\n",
              "                                   'sheet, which totaled $234 million as of '\n",
              "                                   'December 31, 2023.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The proposed acquisition of Fusion is to '\n",
              "                                   'be completed by way of a statutory plan of '\n",
              "                                   'arrangement under the Canada Business '\n",
              "                                   'Corporations Act and subject to customary '\n",
              "                                   'closing conditions, including approval of '\n",
              "                                   '(i) 66⅔% of the votes cast by Fusion '\n",
              "                                   'shareholders and (ii) a simple majority of '\n",
              "                                   'the votes cast by Fusion shareholders '\n",
              "                                   '(excluding certain persons required to be '\n",
              "                                   'excluded in accordance with Multilateral '\n",
              "                                   'Instrument 61-101 of the Canadian '\n",
              "                                   'Securities Administrators), in each case, '\n",
              "                                   'at a special meeting of Fusion '\n",
              "                                   'shareholders. The transaction is expected '\n",
              "                                   'to close in the second quarter of 2024, '\n",
              "                                   'subject to customary closing conditions, '\n",
              "                                   'including the approval of Fusion '\n",
              "                                   'shareholders and regulatory clearances, as '\n",
              "                                   'noted above.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Centerview Partners LLC is serving as '\n",
              "                                   'exclusive financial advisor to Fusion and '\n",
              "                                   'Goodwin Procter LLP is serving as legal '\n",
              "                                   'counsel, with Osler, Hoskin & Harcourt LLP '\n",
              "                                   'serving as Canadian legal counsel.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Radioconjugates in oncology\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs combine the precise targeting of '\n",
              "                                   'antibodies, small molecules or peptides '\n",
              "                                   'with potent medical radioisotopes to '\n",
              "                                   'deliver radiation directly to cancer '\n",
              "                                   'cells. By seeking out cancer cells, RCs '\n",
              "                                   'provide a more precise mechanism of cancer '\n",
              "                                   'cell killing compared with traditional '\n",
              "                                   'radiation therapy, with the goal of '\n",
              "                                   'improving efficacy while minimizing '\n",
              "                                   'toxicity on healthy cells. RCs are '\n",
              "                                   'administered via systemic delivery, which '\n",
              "                                   'enables their use in tumor types not '\n",
              "                                   'accessible to external beam radiation and '\n",
              "                                   'the targeting of cancer cells that have '\n",
              "                                   'spread from the main tumor to other sites '\n",
              "                                   'in the body.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About FPI-2265\\n'\n",
              "                                   '\\n'\n",
              "                                   'FPI-2265 is an actinium-225 based PSMA '\n",
              "                                   'targeting RC, for mCRPC, currently in a '\n",
              "                                   'Phase II trial. Actinium-225 emits alpha '\n",
              "                                   'particles and holds the promise of being a '\n",
              "                                   'next-generation radioisotope in cancer '\n",
              "                                   'treatment. By delivering a greater '\n",
              "                                   'radiation dose over a shorter distance, '\n",
              "                                   'alpha particles such as actinium-225 have '\n",
              "                                   'the potential for more potent cancer cell '\n",
              "                                   'killing, and targeted delivery, thereby '\n",
              "                                   'minimizing damage to surrounding healthy '\n",
              "                                   'tissue.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About Fusion\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Pharmaceuticals is a clinical-stage '\n",
              "                                   'oncology company focused on developing '\n",
              "                                   'next-generation RCs. Fusion connects alpha '\n",
              "                                   'particle emitting isotopes to various '\n",
              "                                   'targeting molecules in order to '\n",
              "                                   'selectively deliver the alpha emitting '\n",
              "                                   \"payloads to tumors. Fusion's \"\n",
              "                                   'clinical-stage development portfolio '\n",
              "                                   'includes lead program, FPI-2265, targeting '\n",
              "                                   'PSMA for mCRPC and novel RCs targeting '\n",
              "                                   'solid tumors.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cautionary Note Regarding Forward-Looking '\n",
              "                                   'Statements\\n'\n",
              "                                   '\\n'\n",
              "                                   'To the extent any statements made in this '\n",
              "                                   'communication contain information that is '\n",
              "                                   'not historical, these statements are '\n",
              "                                   'forward-looking statements within the '\n",
              "                                   'meaning of Section 27A of the U.S. '\n",
              "                                   'Securities Act of 1933, as amended, and '\n",
              "                                   'Section 21E of the U.S. Securities '\n",
              "                                   'Exchange Act of 1934, as amended, and '\n",
              "                                   'forward-looking information under Canadian '\n",
              "                                   'securities law (collectively, '\n",
              "                                   '\"forward-looking statements\"). Certain '\n",
              "                                   'statements in this communication may '\n",
              "                                   'constitute forward-looking statements, '\n",
              "                                   \"which reflect the expectations of Fusion's \"\n",
              "                                   'management regarding the business '\n",
              "                                   'prospects and opportunities of Fusion and '\n",
              "                                   'the proposed transaction. The use of words '\n",
              "                                   'such as \"may,\" \"will,\" \"could,\" \"should,\" '\n",
              "                                   '\"expects,\" \"intends,\" \"plans,\" '\n",
              "                                   '\"anticipates,\" \"believes,\" \"estimates,\" '\n",
              "                                   '\"predicts,\" \"projects,\" \"seeks,\" '\n",
              "                                   '\"endeavor,\" \"potential,\" \"continue\" or the '\n",
              "                                   'negative of such words or other similar '\n",
              "                                   'expressions can be used to identify '\n",
              "                                   'forward-looking statements. More '\n",
              "                                   'particularly and without limitation, this '\n",
              "                                   'communication contains forward-looking '\n",
              "                                   'statements and information regarding '\n",
              "                                   'whether the proposed transaction will be '\n",
              "                                   'completed, whether the CVR Agreement will '\n",
              "                                   'be entered into, the anticipated benefits '\n",
              "                                   'of the proposed transaction for Fusion and '\n",
              "                                   'its Shareholders, whether approval will be '\n",
              "                                   'received under the U.S. Hart-Scott-Rodino '\n",
              "                                   'Antitrust Improvements Act of 1976 and the '\n",
              "                                   'Competition Act (Canada), each as amended, '\n",
              "                                   'and whether the milestone under the CVR '\n",
              "                                   'Agreement will be achieved.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Fusion's actual results could differ \"\n",
              "                                   'materially from those stated or implied in '\n",
              "                                   'forward-looking statements due to a number '\n",
              "                                   'of factors including but not limited to '\n",
              "                                   'risks related to the satisfaction or '\n",
              "                                   'waiver of the conditions to closing the '\n",
              "                                   'proposed transaction (including the '\n",
              "                                   'failure to obtain necessary regulatory, '\n",
              "                                   \"court and Fusion's shareholder approvals) \"\n",
              "                                   'in the anticipated timeframe or at all, '\n",
              "                                   'including the possibility that the '\n",
              "                                   'proposed transaction does not close; the '\n",
              "                                   'response of business partners and '\n",
              "                                   'competitors to the announcement of the '\n",
              "                                   'proposed transaction, and/or potential '\n",
              "                                   'difficulties in employee retention as a '\n",
              "                                   'result of the announcement and pendency of '\n",
              "                                   'the proposed transaction; significant '\n",
              "                                   'transaction costs; the failure to realize '\n",
              "                                   'the expected benefits of the proposed '\n",
              "                                   'transaction; risks associated with the '\n",
              "                                   \"disruption of management's attention from \"\n",
              "                                   'ongoing business operations due to the '\n",
              "                                   'proposed transaction; and unknown '\n",
              "                                   'liabilities and the risk of litigation '\n",
              "                                   'and/or regulatory actions related to the '\n",
              "                                   'proposed transaction. Please also refer to '\n",
              "                                   'the factors discussed under \"Risk Factors\" '\n",
              "                                   'and \"Special Note Regarding '\n",
              "                                   'Forward-looking Information\" in Fusion\\'s '\n",
              "                                   'Annual Report on Form 10-K for the year '\n",
              "                                   'ended December 31, 2022, with the U.S. '\n",
              "                                   'Securities Exchange Commission (\"SEC\"), '\n",
              "                                   \"each as updated by Fusion's continuous \"\n",
              "                                   'disclosure filings, which are available at '\n",
              "                                   'www.sec.gov and at www.sedarplus.com.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Forward-looking statements involve '\n",
              "                                   'significant risks and uncertainties, '\n",
              "                                   'should not be read as guarantees of future '\n",
              "                                   'performance or results, and will not '\n",
              "                                   'necessarily be accurate indications of '\n",
              "                                   'whether or not or the times at or by which '\n",
              "                                   'such performance or results will be '\n",
              "                                   'achieved. All forward-looking statements '\n",
              "                                   'herein are qualified in their entirety by '\n",
              "                                   'its cautionary statement and are made as '\n",
              "                                   'of the date of this document. Fusion '\n",
              "                                   'disclaims any obligation to revise or '\n",
              "                                   'update any such forward-looking statements '\n",
              "                                   'or to publicly announce the result of any '\n",
              "                                   'revisions to any of the forward-looking '\n",
              "                                   'statements contained herein to reflect '\n",
              "                                   'future results, events or developments, '\n",
              "                                   'except as required by law.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Additional Information about the Proposed '\n",
              "                                   'Transaction and Where to Find It\\n'\n",
              "                                   '\\n'\n",
              "                                   'This communication is not intended to and '\n",
              "                                   'does not constitute an offer to sell or '\n",
              "                                   'the solicitation of an offer to subscribe '\n",
              "                                   'for or buy or an invitation to purchase or '\n",
              "                                   'subscribe for any securities or the '\n",
              "                                   'solicitation of any vote, consent or '\n",
              "                                   'approval in any jurisdiction, nor shall '\n",
              "                                   'there by any sale, issuance or transfer of '\n",
              "                                   'securities in any jurisdiction in '\n",
              "                                   'contravention of applicable law. This '\n",
              "                                   'communication has been prepared in respect '\n",
              "                                   'of the transaction involving Fusion, '\n",
              "                                   'AstraZeneca and Purchaser (as defined in '\n",
              "                                   'the Arrangement Agreement) pursuant to the '\n",
              "                                   'terms of the Arrangement Agreement, and '\n",
              "                                   'may be deemed to be soliciting material '\n",
              "                                   'relating to the transaction. In connection '\n",
              "                                   'with the transaction, Fusion will file a '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement on Schedule 14A relating to a '\n",
              "                                   'special meeting of the shareholders with '\n",
              "                                   'the SEC and Canadian Securities '\n",
              "                                   'Administrators (\"CSA\"). Additionally, '\n",
              "                                   'Fusion will file other relevant materials '\n",
              "                                   'in connection with the transaction with '\n",
              "                                   'the SEC and the CSA. Shareholders of '\n",
              "                                   'Fusion are urged to read the management '\n",
              "                                   'information circular and proxy statement '\n",
              "                                   'and/or consent solicitation documents '\n",
              "                                   'regarding the transaction and any other '\n",
              "                                   'relevant materials carefully in their '\n",
              "                                   'entirety when they become available before '\n",
              "                                   'making any voting or investment decision '\n",
              "                                   'with respect to the transaction because '\n",
              "                                   'they will contain important information '\n",
              "                                   'about the transaction and the parties to '\n",
              "                                   'the Arrangement Agreement. The definitive '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement will be mailed to holders of '\n",
              "                                   \"Fusion's shares. Shareholders will be able \"\n",
              "                                   'to obtain a copy of the management '\n",
              "                                   'information circular and proxy statement, '\n",
              "                                   'as well as other filings containing '\n",
              "                                   'information about the transaction and the '\n",
              "                                   'parties to the Arrangement Agreement made '\n",
              "                                   'by Fusion with the SEC and CSA free of '\n",
              "                                   'charge on EDGAR at www.sec.gov , on SEDAR+ '\n",
              "                                   \"at www.sedarplus.com , or on Fusion's \"\n",
              "                                   'website at www.fusionpharma.com . '\n",
              "                                   'Information contained on, or that may be '\n",
              "                                   'accessed through, the websites referenced '\n",
              "                                   'in this communication is not incorporated '\n",
              "                                   'into and does not constitute a part of '\n",
              "                                   'this document. We have included these '\n",
              "                                   'website addresses only as inactive textual '\n",
              "                                   'references and do not intend them to be '\n",
              "                                   'active links.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Participants in the Solicitation\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion and its directors and executive '\n",
              "                                   'officers may be deemed to be participants '\n",
              "                                   'in the solicitation of proxies from the '\n",
              "                                   'shareholders of Fusion in respect of the '\n",
              "                                   \"transaction. Information about Fusion's \"\n",
              "                                   'directors and executive officers is set '\n",
              "                                   'forth in the proxy statement and '\n",
              "                                   'management information circular for '\n",
              "                                   \"Fusion's Annual General Meeting of \"\n",
              "                                   'Shareholders, which was filed with the SEC '\n",
              "                                   'and CSA on April 27, 2023. Investors may '\n",
              "                                   'obtain additional information regarding '\n",
              "                                   'the interest of such participants by '\n",
              "                                   'reading the management information '\n",
              "                                   'circular and proxy statement regarding the '\n",
              "                                   'proposed transaction when it becomes '\n",
              "                                   'available.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact:\\n'\n",
              "                                   '\\n'\n",
              "                                   'Amanda Cray\\n'\n",
              "                                   '\\n'\n",
              "                                   'Senior Director of Investor Relations & '\n",
              "                                   'Corporate Communications\\n'\n",
              "                                   '\\n'\n",
              "                                   '(617) 967-0207\\n'\n",
              "                                   '\\n'\n",
              "                                   'cray@fusionpharma.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'SOURCE Fusion Pharmaceuticals'},\n",
              "              'score': 0.765442908,\n",
              "              'values': []},\n",
              "             {'id': '725',\n",
              "              'metadata': {'text': 'HAMILTON, ON and BOSTON, March 19, 2024 '\n",
              "                                   '/PRNewswire/ — Fusion Pharmaceuticals Inc. '\n",
              "                                   '(Nasdaq: FUSN), a clinical-stage oncology '\n",
              "                                   'company focused on developing '\n",
              "                                   'next-generation radioconjugates (RCs) as '\n",
              "                                   'precision medicines, today announced the '\n",
              "                                   'Company has entered into a definitive '\n",
              "                                   'agreement to be acquired by AstraZeneca. '\n",
              "                                   'The acquisition marks a major step forward '\n",
              "                                   'in AstraZeneca delivering on its ambition '\n",
              "                                   'to transform cancer treatment and outcomes '\n",
              "                                   'for patients by replacing traditional '\n",
              "                                   'regimens like chemotherapy and '\n",
              "                                   'radiotherapy with more targeted '\n",
              "                                   'treatments.\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs have emerged as a promising modality '\n",
              "                                   'in cancer treatment over recent years. '\n",
              "                                   'These medicines deliver a radioactive '\n",
              "                                   'isotope directly to cancer cells through '\n",
              "                                   'precise targeting using molecules such as '\n",
              "                                   'antibodies, peptides or small molecules. '\n",
              "                                   'This approach has many potential '\n",
              "                                   'advantages compared to traditional '\n",
              "                                   'radiotherapy, including minimizing damage '\n",
              "                                   'to healthy cells and enabling access to '\n",
              "                                   'tumors not reachable through external beam '\n",
              "                                   'radiation.\\n'\n",
              "                                   '\\n'\n",
              "                                   'This acquisition complements AstraZeneca’s '\n",
              "                                   'leading oncology portfolio with the '\n",
              "                                   'addition of the Fusion pipeline of RCs, '\n",
              "                                   'including the Company’s most advanced '\n",
              "                                   'program, FPI-2265, a potential new '\n",
              "                                   'treatment for patients with metastatic '\n",
              "                                   'castration-resistant prostate cancer '\n",
              "                                   '(mCRPC). FPI-2265 targets '\n",
              "                                   'prostate-specific membrane antigen (PSMA), '\n",
              "                                   'a protein that is highly expressed in '\n",
              "                                   'mCRPC, and is currently in a Phase 2 '\n",
              "                                   'trial.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The acquisition brings new expertise and '\n",
              "                                   'pioneering R&D, manufacturing and supply '\n",
              "                                   'chain capabilities in actinium-based RCs '\n",
              "                                   'to AstraZeneca. It also strengthens their '\n",
              "                                   'presence in and commitment to Canada.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Chief Executive Officer John '\n",
              "                                   'Valliant, Ph.D., said: “This acquisition '\n",
              "                                   'combines Fusion’s expertise and '\n",
              "                                   'capabilities in radioconjugates, including '\n",
              "                                   'our industry-leading radiopharmaceutical '\n",
              "                                   'R&D, pipeline, manufacturing and '\n",
              "                                   'actinium-225 supply chain, with '\n",
              "                                   'AstraZeneca’s leadership in small '\n",
              "                                   'molecules and biologics engineering to '\n",
              "                                   'develop novel radioconjugates. Expanding '\n",
              "                                   'on our existing collaboration with '\n",
              "                                   'AstraZeneca where we have advanced '\n",
              "                                   'FPI-2068, an EGFR-cMET targeted '\n",
              "                                   'radioconjugate into Phase I clinical '\n",
              "                                   'trials, gives us a unique opportunity to '\n",
              "                                   'accelerate the development of '\n",
              "                                   'next-generation radioconjugates with the '\n",
              "                                   'aim of transforming patient outcomes.”\\n'\n",
              "                                   '\\n'\n",
              "                                   'Susan Galbraith, Executive Vice President, '\n",
              "                                   'Oncology R&D, AstraZeneca, said: “Between '\n",
              "                                   'thirty and fifty per cent of patients with '\n",
              "                                   'cancer today receive radiotherapy at some '\n",
              "                                   'point during treatment, and the '\n",
              "                                   'acquisition of Fusion furthers our '\n",
              "                                   'ambition to transform this aspect of care '\n",
              "                                   'with next-generation radioconjugates. '\n",
              "                                   'Together with Fusion, we have an '\n",
              "                                   'opportunity to accelerate the development '\n",
              "                                   'of FPI-2265 as a potential new treatment '\n",
              "                                   'for prostate cancer, and to harness their '\n",
              "                                   'innovative actinium-based platform to '\n",
              "                                   'develop radioconjugates as foundational '\n",
              "                                   'regimens.”\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion President and Chief Business '\n",
              "                                   'Officer Mohit Rawat, said: “Fusion has '\n",
              "                                   'differentiated itself in the growing '\n",
              "                                   'radioconjugate space by assembling an '\n",
              "                                   'industry-leading team with deep expertise '\n",
              "                                   'and infrastructure to support bringing '\n",
              "                                   'these much-needed therapies to cancer '\n",
              "                                   'patients. Together we look forward to '\n",
              "                                   'building upon our work to impact the '\n",
              "                                   'landscape of cancer therapy. Deepening our '\n",
              "                                   'collaboration with AstraZeneca presents an '\n",
              "                                   'exciting opportunity for the Fusion '\n",
              "                                   'team.”\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion will become a wholly owned '\n",
              "                                   'subsidiary of AstraZeneca, with operations '\n",
              "                                   'continuing in Canada and the US.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Financial Considerations\\n'\n",
              "                                   '\\n'\n",
              "                                   'Under the terms of the definitive '\n",
              "                                   'agreement, AstraZeneca, through a '\n",
              "                                   'subsidiary, will acquire all of Fusion’s '\n",
              "                                   'outstanding shares pursuant to a plan of '\n",
              "                                   'arrangement for a price of $21.00 per '\n",
              "                                   'share in cash at closing plus a '\n",
              "                                   'non-transferable contingent value right '\n",
              "                                   '(CVR) of $3.00 per share in cash payable '\n",
              "                                   'upon the achievement of a specified '\n",
              "                                   'regulatory milestone.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The upfront cash portion of the '\n",
              "                                   'consideration represents a transaction '\n",
              "                                   'value of approximately $2 billion, a 97% '\n",
              "                                   'premium to Fusion’s closing market price '\n",
              "                                   'of $10.64 on March 18, 2024, and an 85% '\n",
              "                                   'premium to the 30-day volume-weighted '\n",
              "                                   'average price (VWAP) of $11.37 before this '\n",
              "                                   'announcement. Combined, the upfront and '\n",
              "                                   'maximum potential contingent value '\n",
              "                                   'payments represent, if achieved, a '\n",
              "                                   'transaction value of approximately $2.4 '\n",
              "                                   'billion, a 126% premium to Fusion’s '\n",
              "                                   'closing market price on March 18, 2024, '\n",
              "                                   'and a 111% premium to the 30-day VWAP. As '\n",
              "                                   'part of the transaction, AstraZeneca will '\n",
              "                                   'acquire the cash, cash equivalents and '\n",
              "                                   'short-term investments on Fusion’s balance '\n",
              "                                   'sheet, which totaled $234 million as of '\n",
              "                                   'December 31, 2023.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The proposed acquisition of Fusion is to '\n",
              "                                   'be completed by way of a statutory plan of '\n",
              "                                   'arrangement under the Canada Business '\n",
              "                                   'Corporations Act and subject to customary '\n",
              "                                   'closing conditions, including approval of '\n",
              "                                   '(i) 66⅔% of the votes cast by Fusion '\n",
              "                                   'shareholders and (ii) a simple majority of '\n",
              "                                   'the votes cast by Fusion shareholders '\n",
              "                                   '(excluding certain persons required to be '\n",
              "                                   'excluded in accordance with Multilateral '\n",
              "                                   'Instrument 61-101 of the Canadian '\n",
              "                                   'Securities Administrators), in each case, '\n",
              "                                   'at a special meeting of Fusion '\n",
              "                                   'shareholders. The transaction is expected '\n",
              "                                   'to close in the second quarter of 2024, '\n",
              "                                   'subject to customary closing conditions, '\n",
              "                                   'including the approval of Fusion '\n",
              "                                   'shareholders and regulatory clearances, as '\n",
              "                                   'noted above.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Centerview Partners LLC is serving as '\n",
              "                                   'exclusive financial advisor to Fusion and '\n",
              "                                   'Goodwin Procter LLP is serving as legal '\n",
              "                                   'counsel, with Osler, Hoskin & Harcourt LLP '\n",
              "                                   'serving as Canadian legal counsel.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Radioconjugates in oncology\\n'\n",
              "                                   '\\n'\n",
              "                                   'RCs combine the precise targeting of '\n",
              "                                   'antibodies, small molecules or peptides '\n",
              "                                   'with potent medical radioisotopes to '\n",
              "                                   'deliver radiation directly to cancer '\n",
              "                                   'cells. By seeking out cancer cells, RCs '\n",
              "                                   'provide a more precise mechanism of cancer '\n",
              "                                   'cell killing compared with traditional '\n",
              "                                   'radiation therapy, with the goal of '\n",
              "                                   'improving efficacy while minimizing '\n",
              "                                   'toxicity on healthy cells. RCs are '\n",
              "                                   'administered via systemic delivery, which '\n",
              "                                   'enables their use in tumor types not '\n",
              "                                   'accessible to external beam radiation and '\n",
              "                                   'the targeting of cancer cells that have '\n",
              "                                   'spread from the main tumor to other sites '\n",
              "                                   'in the body.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About FPI-2265\\n'\n",
              "                                   '\\n'\n",
              "                                   'FPI-2265 is an actinium-225 based PSMA '\n",
              "                                   'targeting RC, for mCRPC, currently in a '\n",
              "                                   'Phase II trial. Actinium-225 emits alpha '\n",
              "                                   'particles and holds the promise of being a '\n",
              "                                   'next-generation radioisotope in cancer '\n",
              "                                   'treatment. By delivering a greater '\n",
              "                                   'radiation dose over a shorter distance, '\n",
              "                                   'alpha particles such as actinium-225 have '\n",
              "                                   'the potential for more potent cancer cell '\n",
              "                                   'killing, and targeted delivery, thereby '\n",
              "                                   'minimizing damage to surrounding healthy '\n",
              "                                   'tissue.\\n'\n",
              "                                   '\\n'\n",
              "                                   'About Fusion\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion Pharmaceuticals is a clinical-stage '\n",
              "                                   'oncology company focused on developing '\n",
              "                                   'next-generation RCs. Fusion connects alpha '\n",
              "                                   'particle emitting isotopes to various '\n",
              "                                   'targeting molecules in order to '\n",
              "                                   'selectively deliver the alpha emitting '\n",
              "                                   'payloads to tumors. Fusion’s '\n",
              "                                   'clinical-stage development portfolio '\n",
              "                                   'includes lead program, FPI-2265, targeting '\n",
              "                                   'PSMA for mCRPC and novel RCs targeting '\n",
              "                                   'solid tumors.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cautionary Note Regarding Forward-Looking '\n",
              "                                   'Statements\\n'\n",
              "                                   '\\n'\n",
              "                                   'To the extent any statements made in this '\n",
              "                                   'communication contain information that is '\n",
              "                                   'not historical, these statements are '\n",
              "                                   'forward-looking statements within the '\n",
              "                                   'meaning of Section 27A of the U.S. '\n",
              "                                   'Securities Act of 1933, as amended, and '\n",
              "                                   'Section 21E of the U.S. Securities '\n",
              "                                   'Exchange Act of 1934, as amended, and '\n",
              "                                   'forward-looking information under Canadian '\n",
              "                                   'securities law (collectively, '\n",
              "                                   '“forward-looking statements”). Certain '\n",
              "                                   'statements in this communication may '\n",
              "                                   'constitute forward-looking statements, '\n",
              "                                   'which reflect the expectations of Fusion’s '\n",
              "                                   'management regarding the business '\n",
              "                                   'prospects and opportunities of Fusion and '\n",
              "                                   'the proposed transaction. The use of words '\n",
              "                                   'such as “may,” “will,” “could,” “should,” '\n",
              "                                   '“expects,” “intends,” “plans,” '\n",
              "                                   '“anticipates,” “believes,” “estimates,” '\n",
              "                                   '“predicts,” “projects,” “seeks,” '\n",
              "                                   '“endeavor,” “potential,” “continue” or the '\n",
              "                                   'negative of such words or other similar '\n",
              "                                   'expressions can be used to identify '\n",
              "                                   'forward-looking statements. More '\n",
              "                                   'particularly and without limitation, this '\n",
              "                                   'communication contains forward-looking '\n",
              "                                   'statements and information regarding '\n",
              "                                   'whether the proposed transaction will be '\n",
              "                                   'completed, whether the CVR Agreement will '\n",
              "                                   'be entered into, the anticipated benefits '\n",
              "                                   'of the proposed transaction for Fusion and '\n",
              "                                   'its Shareholders, whether approval will be '\n",
              "                                   'received under the U.S. Hart-Scott-Rodino '\n",
              "                                   'Antitrust Improvements Act of 1976 and the '\n",
              "                                   'Competition Act (Canada), each as amended, '\n",
              "                                   'and whether the milestone under the CVR '\n",
              "                                   'Agreement will be achieved.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion’s actual results could differ '\n",
              "                                   'materially from those stated or implied in '\n",
              "                                   'forward-looking statements due to a number '\n",
              "                                   'of factors including but not limited to '\n",
              "                                   'risks related to the satisfaction or '\n",
              "                                   'waiver of the conditions to closing the '\n",
              "                                   'proposed transaction (including the '\n",
              "                                   'failure to obtain necessary regulatory, '\n",
              "                                   'court and Fusion’s shareholder approvals) '\n",
              "                                   'in the anticipated timeframe or at all, '\n",
              "                                   'including the possibility that the '\n",
              "                                   'proposed transaction does not close; the '\n",
              "                                   'response of business partners and '\n",
              "                                   'competitors to the announcement of the '\n",
              "                                   'proposed transaction, and/or potential '\n",
              "                                   'difficulties in employee retention as a '\n",
              "                                   'result of the announcement and pendency of '\n",
              "                                   'the proposed transaction; significant '\n",
              "                                   'transaction costs; the failure to realize '\n",
              "                                   'the expected benefits of the proposed '\n",
              "                                   'transaction; risks associated with the '\n",
              "                                   'disruption of management’s attention from '\n",
              "                                   'ongoing business operations due to the '\n",
              "                                   'proposed transaction; and unknown '\n",
              "                                   'liabilities and the risk of litigation '\n",
              "                                   'and/or regulatory actions related to the '\n",
              "                                   'proposed transaction. Please also refer to '\n",
              "                                   'the factors discussed under “Risk Factors” '\n",
              "                                   'and “Special Note Regarding '\n",
              "                                   'Forward-looking Information” in Fusion’s '\n",
              "                                   'Annual Report on Form 10-K for the year '\n",
              "                                   'ended December 31, 2022, with the U.S. '\n",
              "                                   'Securities Exchange Commission (“SEC”), '\n",
              "                                   'each as updated by Fusion’s continuous '\n",
              "                                   'disclosure filings, which are available at '\n",
              "                                   'www.sec.gov and at www.sedarplus.com.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Forward-looking statements involve '\n",
              "                                   'significant risks and uncertainties, '\n",
              "                                   'should not be read as guarantees of future '\n",
              "                                   'performance or results, and will not '\n",
              "                                   'necessarily be accurate indications of '\n",
              "                                   'whether or not or the times at or by which '\n",
              "                                   'such performance or results will be '\n",
              "                                   'achieved. All forward-looking statements '\n",
              "                                   'herein are qualified in their entirety by '\n",
              "                                   'its cautionary statement and are made as '\n",
              "                                   'of the date of this document. Fusion '\n",
              "                                   'disclaims any obligation to revise or '\n",
              "                                   'update any such forward-looking statements '\n",
              "                                   'or to publicly announce the result of any '\n",
              "                                   'revisions to any of the forward-looking '\n",
              "                                   'statements contained herein to reflect '\n",
              "                                   'future results, events or developments, '\n",
              "                                   'except as required by law.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Additional Information about the Proposed '\n",
              "                                   'Transaction and Where to Find It\\n'\n",
              "                                   '\\n'\n",
              "                                   'This communication is not intended to and '\n",
              "                                   'does not constitute an offer to sell or '\n",
              "                                   'the solicitation of an offer to subscribe '\n",
              "                                   'for or buy or an invitation to purchase or '\n",
              "                                   'subscribe for any securities or the '\n",
              "                                   'solicitation of any vote, consent or '\n",
              "                                   'approval in any jurisdiction, nor shall '\n",
              "                                   'there by any sale, issuance or transfer of '\n",
              "                                   'securities in any jurisdiction in '\n",
              "                                   'contravention of applicable law. This '\n",
              "                                   'communication has been prepared in respect '\n",
              "                                   'of the transaction involving Fusion, '\n",
              "                                   'AstraZeneca and Purchaser (as defined in '\n",
              "                                   'the Arrangement Agreement) pursuant to the '\n",
              "                                   'terms of the Arrangement Agreement, and '\n",
              "                                   'may be deemed to be soliciting material '\n",
              "                                   'relating to the transaction. In connection '\n",
              "                                   'with the transaction, Fusion will file a '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement on Schedule 14A relating to a '\n",
              "                                   'special meeting of the shareholders with '\n",
              "                                   'the SEC and Canadian Securities '\n",
              "                                   'Administrators (“CSA”). Additionally, '\n",
              "                                   'Fusion will file other relevant materials '\n",
              "                                   'in connection with the transaction with '\n",
              "                                   'the SEC and the CSA. Shareholders of '\n",
              "                                   'Fusion are urged to read the management '\n",
              "                                   'information circular and proxy statement '\n",
              "                                   'and/or consent solicitation documents '\n",
              "                                   'regarding the transaction and any other '\n",
              "                                   'relevant materials carefully in their '\n",
              "                                   'entirety when they become available before '\n",
              "                                   'making any voting or investment decision '\n",
              "                                   'with respect to the transaction because '\n",
              "                                   'they will contain important information '\n",
              "                                   'about the transaction and the parties to '\n",
              "                                   'the Arrangement Agreement. The definitive '\n",
              "                                   'management information circular and proxy '\n",
              "                                   'statement will be mailed to holders of '\n",
              "                                   'Fusion’s shares. Shareholders will be able '\n",
              "                                   'to obtain a copy of the management '\n",
              "                                   'information circular and proxy statement, '\n",
              "                                   'as well as other filings containing '\n",
              "                                   'information about the transaction and the '\n",
              "                                   'parties to the Arrangement Agreement made '\n",
              "                                   'by Fusion with the SEC and CSA free of '\n",
              "                                   'charge on EDGAR at www.sec.gov, on SEDAR+ '\n",
              "                                   'at www.sedarplus.com, or on Fusion’s '\n",
              "                                   'website at www.fusionpharma.com. '\n",
              "                                   'Information contained on, or that may be '\n",
              "                                   'accessed through, the websites referenced '\n",
              "                                   'in this communication is not incorporated '\n",
              "                                   'into and does not constitute a part of '\n",
              "                                   'this document. We have included these '\n",
              "                                   'website addresses only as inactive textual '\n",
              "                                   'references and do not intend them to be '\n",
              "                                   'active links.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Participants in the Solicitation\\n'\n",
              "                                   '\\n'\n",
              "                                   'Fusion and its directors and executive '\n",
              "                                   'officers may be deemed to be participants '\n",
              "                                   'in the solicitation of proxies from the '\n",
              "                                   'shareholders of Fusion in respect of the '\n",
              "                                   'transaction. Information about Fusion’s '\n",
              "                                   'directors and executive officers is set '\n",
              "                                   'forth in the proxy statement and '\n",
              "                                   'management information circular for '\n",
              "                                   'Fusion’s Annual General Meeting of '\n",
              "                                   'Shareholders, which was filed with the SEC '\n",
              "                                   'and CSA on April 27, 2023. Investors may '\n",
              "                                   'obtain additional information regarding '\n",
              "                                   'the interest of such participants by '\n",
              "                                   'reading the management information '\n",
              "                                   'circular and proxy statement regarding the '\n",
              "                                   'proposed transaction when it becomes '\n",
              "                                   'available.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact:\\n'\n",
              "                                   '\\n'\n",
              "                                   'Amanda Cray\\n'\n",
              "                                   '\\n'\n",
              "                                   'Senior Director of Investor Relations & '\n",
              "                                   'Corporate Communications\\n'\n",
              "                                   '\\n'\n",
              "                                   '(617) 967-0207\\n'\n",
              "                                   '\\n'\n",
              "                                   'cray@fusionpharma.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'SOURCE Fusion Pharmaceuticals'},\n",
              "              'score': 0.761225939,\n",
              "              'values': []},\n",
              "             {'id': '55',\n",
              "              'metadata': {'text': 'Cantor Fitzgerald sees another strong year '\n",
              "                                   'ahead for oncology M&A, with companies '\n",
              "                                   'focused on antibody drug conjugates, '\n",
              "                                   'radiopharmaceuticals and T-cell engagers '\n",
              "                                   'expected to attract increased attention '\n",
              "                                   'from major drugmakers looking to replenish '\n",
              "                                   'pipelines.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Impending patent cliffs will be a big '\n",
              "                                   'motivator for deals. According to Cantor, '\n",
              "                                   'around $182B in revenue is at risk over '\n",
              "                                   'the next four years due to patent '\n",
              "                                   'expirations, with oncology products '\n",
              "                                   'accounting for 42% of that number.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Several of the industry's biggest are set \"\n",
              "                                   'to lose patent protection by 2029, '\n",
              "                                   'including Bristol Myers (BMY) Yervoy, '\n",
              "                                   'Pomalyst and Opdivo; Johnson & Johnson’s '\n",
              "                                   '(JNJ) Imbruvica; Merck’s (MRK) Keytruda; '\n",
              "                                   'Pfizer’s (PFE) Ibrance; and Roche’s '\n",
              "                                   '(OTCQX:RHHBY) Perjeta, according to '\n",
              "                                   'Cantor.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Meanwhile, the global market for oncology '\n",
              "                                   'drugs is expected to grow from $180B in '\n",
              "                                   '2022 to $323B in 2028, a rate that is '\n",
              "                                   '“unparalleled to other therapeutics '\n",
              "                                   'areas,” Cantor said. In comparison, the '\n",
              "                                   'global biopharmaceutical market is '\n",
              "                                   'expected to swell from $978B in 2022 to '\n",
              "                                   '$1.39T in 2028.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cantor estimates the industry should see '\n",
              "                                   'between five and 17 acquisition deals this '\n",
              "                                   'year, noting that three have already been '\n",
              "                                   'announced to date: J&J/Ambrx (AMAM), '\n",
              "                                   'Merck/Harpoon (HARP), and Novartis '\n",
              "                                   '(NVS)/Morphosys (MOR).\\n'\n",
              "                                   '\\n'\n",
              "                                   'The investment bank also pointed out that '\n",
              "                                   'the pool of potential buyers is fairly '\n",
              "                                   'deep as pretty much every major drugmaker '\n",
              "                                   'has a presence in oncology, with Novo '\n",
              "                                   'Nordisk (NVO) being a notable exception.\\n'\n",
              "                                   '\\n'\n",
              "                                   'So what type of assets will Big Pharma be '\n",
              "                                   'seeking out?\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cantor still sees a preference for '\n",
              "                                   'de-risked assets but noted that '\n",
              "                                   'proof-of-concept data for oncology drugs '\n",
              "                                   'can often be achieved in Phase 1/2 '\n",
              "                                   'testing. Drug candidates addressing larger '\n",
              "                                   'markets, such as breast, lung or '\n",
              "                                   'colorectal cancer, should be particularly '\n",
              "                                   'attractive to potential buyers.\\n'\n",
              "                                   '\\n'\n",
              "                                   'While small molecule candidates will '\n",
              "                                   'probably account for around 50% of the '\n",
              "                                   'deals, Cantor says complex biologics have '\n",
              "                                   'been gaining in popularity. The bank sees '\n",
              "                                   'assets such as antibody drug conjugates, '\n",
              "                                   'radiopharmaceuticals and T-cell engagers '\n",
              "                                   'as being particularly attractive '\n",
              "                                   'acquisition targets this year, while '\n",
              "                                   'synthetic lethality and TCR therapies '\n",
              "                                   'could also see increased interest.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Cantor sees several companies in its '\n",
              "                                   'coverage universe as potentially '\n",
              "                                   'attracting suitors this year, including '\n",
              "                                   'Kura (NASDAQ:KURA), Bicycle (NASDAQ:BCYC), '\n",
              "                                   'Immunocore (NASDAQ:IMCR), ALX Oncology '\n",
              "                                   '(NASDAQ:ALXO), Arvinas (ARVN), Immatics '\n",
              "                                   '(IMTX), Verastem (VSTM), Oric (ORIC), and '\n",
              "                                   'CG Oncology (NASDAQ:CGON).\\n'\n",
              "                                   '\\n'\n",
              "                                   'Potential targets outside of its coverage '\n",
              "                                   'include Day One (DAWN), Deciphera (DCPH), '\n",
              "                                   'Erasca (ERAS), Exelixis (EXEL), Fusion '\n",
              "                                   '(FUSN), Geron (GERN), Ideaya (IDYA), '\n",
              "                                   'Karyopharm (KPTI), Janux (JANX), Legend '\n",
              "                                   'Biotech (LEGN), Merus (MRUS), Nuvalent '\n",
              "                                   '(NUVL), Olmea (OLMA), PMV (PMVP), Relay '\n",
              "                                   'Therapeutics(RLAY), Revolution Medicines '\n",
              "                                   '(RVMD), Syndax (SNDX), SpringWorks '\n",
              "                                   'Therapeutics (SWTX), UroGen (URGN), and '\n",
              "                                   'Zentalis (ZNTL).'},\n",
              "              'score': 0.738520622,\n",
              "              'values': []},\n",
              "             {'id': '1161',\n",
              "              'metadata': {'text': 'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\"Biotech Stocks In Focus\"\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Dr. Kumar will discuss Anixa's portfolio \"\n",
              "                                   'of first-in-class oncology/immunology '\n",
              "                                   'assets under development, with vaccines to '\n",
              "                                   'prevent cancer and a CAR-T cell therapy to '\n",
              "                                   \"treat cancer. The Company's robust \"\n",
              "                                   'pipeline over the next 12 months includes '\n",
              "                                   'three candidates based on two modalities, '\n",
              "                                   'three indications, and two ongoing '\n",
              "                                   'clinical trials.\\n'\n",
              "                                   '\\n'\n",
              "                                   '2023 witnessed a remarkable flurry of '\n",
              "                                   'activity in the biopharmaceutical '\n",
              "                                   'industry, with several high-profile '\n",
              "                                   \"acquisitions underscoring the sector's \"\n",
              "                                   'dynamic nature and its relentless pursuit '\n",
              "                                   'of innovation. Here’s a look at some of '\n",
              "                                   'the most significant deals that not only '\n",
              "                                   'made headlines but are set to reshape the '\n",
              "                                   'therapeutic landscape.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Before we get into the recent M and A’s, '\n",
              "                                   'one biotech company that we would like to '\n",
              "                                   'draw your attention to is Anixa '\n",
              "                                   'Biosciences ANIX. Shares of Anixa '\n",
              "                                   'Biosciences ANIX are up over 15% in the '\n",
              "                                   'last 5 days.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Amid the wave of acquisitions sweeping '\n",
              "                                   'through the biopharmaceutical sector, '\n",
              "                                   'could Anixa Biosciences ANIX emerge as a '\n",
              "                                   'potential compelling contender for buyout '\n",
              "                                   'consideration?. As a clinical-stage '\n",
              "                                   'biotechnology company, Anixa is at the '\n",
              "                                   'forefront of cancer treatment and '\n",
              "                                   'prevention, wielding a portfolio that '\n",
              "                                   'could attract interest from larger '\n",
              "                                   'pharmaceutical firms looking to diversify '\n",
              "                                   'and enrich their oncology and '\n",
              "                                   'immunotherapy offerings.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Anixa’s Anixa Biosciences ANIX pioneering '\n",
              "                                   'work includes a collaboration with Moffitt '\n",
              "                                   'Cancer Center on an ovarian cancer '\n",
              "                                   'immunotherapy program that leverages '\n",
              "                                   'cutting-edge chimeric endocrine receptor '\n",
              "                                   'T-cell (CER-T) technology. This innovation '\n",
              "                                   'represents a novel approach within the '\n",
              "                                   'CAR-T therapeutic space, potentially '\n",
              "                                   'offering a new avenue for treating a '\n",
              "                                   'variety of cancers. Furthermore, Anixa’s '\n",
              "                                   'vaccine development efforts, including a '\n",
              "                                   'groundbreaking vaccine against triple '\n",
              "                                   'negative breast cancer (TNBC) in '\n",
              "                                   'collaboration with Cleveland Clinic, '\n",
              "                                   'positions the company as a leader in '\n",
              "                                   'prophylactic treatments for some of the '\n",
              "                                   'most challenging forms of cancer. The '\n",
              "                                   'vaccine’s focus on “retired” proteins, '\n",
              "                                   'expressed in certain cancers, exemplifies '\n",
              "                                   'Anixa’s commitment to novel and '\n",
              "                                   'potentially transformative therapeutic '\n",
              "                                   'strategies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Anixa’s business model, characterized by '\n",
              "                                   'strategic partnerships with renowned '\n",
              "                                   'research institutions for the clinical '\n",
              "                                   'development of emerging technologies, '\n",
              "                                   'enhances its attractiveness as a buyout '\n",
              "                                   'candidate. This collaborative approach not '\n",
              "                                   'only accelerates the pace of innovation '\n",
              "                                   'but also mitigates some of the risks '\n",
              "                                   'typically associated with drug development '\n",
              "                                   'by pooling expertise and resources.\\n'\n",
              "                                   '\\n'\n",
              "                                   'In a notable display of confidence in '\n",
              "                                   'Anixa Biosciences’ potential and '\n",
              "                                   'direction, two key insiders made '\n",
              "                                   \"significant purchases of the company's \"\n",
              "                                   'stock on March 15, 2024, signaling strong '\n",
              "                                   'belief in the future of their innovative '\n",
              "                                   'cancer therapies. Amit Kumar, the Chief '\n",
              "                                   'Executive Officer of Anixa Biosciences, '\n",
              "                                   'invested directly in the company by '\n",
              "                                   'purchasing 30,000 shares at a price of '\n",
              "                                   '$3.22 per share, totaling an investment of '\n",
              "                                   '$96,600. Similarly, Arnold M. Baskies, a '\n",
              "                                   'director of the company, demonstrated his '\n",
              "                                   'commitment and optimism by acquiring '\n",
              "                                   '10,000 shares directly at a price of $3.63 '\n",
              "                                   'per share, amounting to an investment of '\n",
              "                                   '$36,300. These transactions underscore the '\n",
              "                                   \"leadership's confidence in Anixa \"\n",
              "                                   \"Biosciences' strategic initiatives and its \"\n",
              "                                   'continued growth within the '\n",
              "                                   'biopharmaceutical sector, especially at a '\n",
              "                                   'time when the company is making '\n",
              "                                   'significant strides in the development of '\n",
              "                                   'breakthrough cancer therapies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Given the current climate of robust M&A '\n",
              "                                   'activity in the biopharmaceutical '\n",
              "                                   'industry, driven by a quest for innovative '\n",
              "                                   'cancer treatments and preventive '\n",
              "                                   'therapies, Anixa Biosciences potentially '\n",
              "                                   'stands out as a prime candidate for '\n",
              "                                   'acquisition. The company’s unique '\n",
              "                                   'combination of advanced therapeutic and '\n",
              "                                   'vaccine technologies, along with its '\n",
              "                                   'strategic alliances, makes it an '\n",
              "                                   'attractive target for larger entities '\n",
              "                                   'seeking to bolster their pipelines with '\n",
              "                                   'promising, high-impact oncology '\n",
              "                                   'solutions.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"At the forefront of 2023's M&A activity, \"\n",
              "                                   \"Pfizer's PFE monumental $43 billion merger \"\n",
              "                                   'with Seagen stood out, catalyzing '\n",
              "                                   'widespread interest in the burgeoning '\n",
              "                                   'field of antibody-drug conjugates (ADCs). '\n",
              "                                   'This strategic move is part of Pfizer’s '\n",
              "                                   'broader diversification strategy, '\n",
              "                                   'especially at a time when its financial '\n",
              "                                   'performance was under pressure due to '\n",
              "                                   'dwindling demand for COVID-19 products. '\n",
              "                                   \"Pfizer's acquisition of Seagen not only \"\n",
              "                                   'enhances its oncology portfolio with four '\n",
              "                                   'commercial cancer products, including the '\n",
              "                                   'high-potential bladder cancer treatment '\n",
              "                                   'Padcev, but also sets the stage for '\n",
              "                                   \"accelerated development of Seagen's robust \"\n",
              "                                   \"pipeline through Pfizer's R&D, \"\n",
              "                                   'commercialization, and manufacturing '\n",
              "                                   'prowess.\\n'\n",
              "                                   '\\n'\n",
              "                                   'AbbVie’s ABBV proposed acquisition of '\n",
              "                                   'ImmunoGen for $10.1 billion is another '\n",
              "                                   \"testament to the industry's intensified \"\n",
              "                                   'focus on ADCs. This deal positions AbbVie '\n",
              "                                   'within the solid tumor space, capitalizing '\n",
              "                                   'on ImmunoGen’s expertise and its approved '\n",
              "                                   'drug Elahere for advanced ovarian cancer. '\n",
              "                                   'ImmunoGen brings to AbbVie a deep well of '\n",
              "                                   'ADC knowledge and a pipeline poised for '\n",
              "                                   'further breakthroughs.\\n'\n",
              "                                   '\\n'\n",
              "                                   'In a deal valued at $14 billion, Bristol '\n",
              "                                   'Myers Squibb’s BMY acquisition of Karuna '\n",
              "                                   'Therapeutics underscores its commitment to '\n",
              "                                   \"pioneering neuroscience. Karuna's lead \"\n",
              "                                   'asset, KarXT, a novel treatment for '\n",
              "                                   'schizophrenia, has the potential to '\n",
              "                                   'revolutionize the treatment landscape with '\n",
              "                                   'its unique mechanism and broader '\n",
              "                                   'therapeutic applications, including '\n",
              "                                   'Alzheimer’s disease psychosis. This '\n",
              "                                   \"acquisition significantly bolsters BMS's \"\n",
              "                                   'neuropsychiatry pipeline and sets a new '\n",
              "                                   'course in mental health treatment.\\n'\n",
              "                                   '\\n'\n",
              "                                   \"Merck's MRK acquisition of Prometheus \"\n",
              "                                   'Biosciences for $10.8 billion marked a '\n",
              "                                   'significant expansion of its immunology '\n",
              "                                   'footprint. The deal centered around '\n",
              "                                   \"Prometheus's promising TL1A inhibitor, \"\n",
              "                                   'PRA-023, for ulcerative colitis and '\n",
              "                                   \"Crohn's disease, showcasing the drug's \"\n",
              "                                   'potential to lead in a competitive space. '\n",
              "                                   'This acquisition not only diversifies '\n",
              "                                   'Merck’s portfolio but also reinforces its '\n",
              "                                   'commitment to addressing unmet medical '\n",
              "                                   'needs in immunology.\\n'\n",
              "                                   '\\n'\n",
              "                                   'AbbVie’s ABBV purchase of Cerevel '\n",
              "                                   'Therapeutics for $8.7 billion late in the '\n",
              "                                   'year signals a strong belief in the '\n",
              "                                   'resurgence of neuroscience. Cerevel brings '\n",
              "                                   'a rich pipeline of potential blockbuster '\n",
              "                                   'neurotherapeutics, including emraclidine '\n",
              "                                   'for schizophrenia and Alzheimer’s disease '\n",
              "                                   'psychosis. This deal is set to '\n",
              "                                   'significantly enhance AbbVie’s presence in '\n",
              "                                   'the neurological disorders market.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Biogen’s BIIB acquisition of Reata '\n",
              "                                   'Pharmaceuticals for $7.3 billion focuses '\n",
              "                                   'on Skyclarys, the first FDA-approved '\n",
              "                                   'treatment for Friedreich’s ataxia. This '\n",
              "                                   'deal reflects Biogen’s strategy to lead in '\n",
              "                                   'the treatment of rare neurological '\n",
              "                                   'disorders, further solidifying its '\n",
              "                                   'portfolio of innovative neurological '\n",
              "                                   'therapies.\\n'\n",
              "                                   '\\n'\n",
              "                                   'These transactions highlight the '\n",
              "                                   \"biopharmaceutical industry's strategic \"\n",
              "                                   'focus on innovation, diversification, and '\n",
              "                                   'specialization. As these companies '\n",
              "                                   'integrate their new acquisitions, the '\n",
              "                                   'healthcare landscape anticipates '\n",
              "                                   'groundbreaking advancements in treatment '\n",
              "                                   'options and patient care. The year 2023 '\n",
              "                                   'has set a remarkable precedent for the '\n",
              "                                   'future of biopharma M&A, underscoring the '\n",
              "                                   \"industry's resilience and its commitment \"\n",
              "                                   'to advancing human health.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Loading... Loading...\\n'\n",
              "                                   '\\n'\n",
              "                                   'In summary, Anixa Biosciences, with its '\n",
              "                                   'innovative approach to cancer '\n",
              "                                   'immunotherapy and preventive vaccines, is '\n",
              "                                   'potentially, uniquely positioned at the '\n",
              "                                   'intersection of pioneering research and '\n",
              "                                   \"clinical application. The company's \"\n",
              "                                   'strategic collaborations and focus on '\n",
              "                                   'groundbreaking technologies like CER-T and '\n",
              "                                   'vaccines targeting TNBC and ovarian cancer '\n",
              "                                   'make it a standout candidate for '\n",
              "                                   'acquisition in the rapidly evolving '\n",
              "                                   'biopharmaceutical landscape. As the '\n",
              "                                   'industry continues to seek out novel '\n",
              "                                   'solutions for cancer treatment and '\n",
              "                                   \"prevention, Anixa's Anixa Biosciences ANIX \"\n",
              "                                   'trajectory suggests it could potentially '\n",
              "                                   'play a pivotal role in shaping the future '\n",
              "                                   'of oncology.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Disclaimer: This article is for '\n",
              "                                   'informational purposes only and does not '\n",
              "                                   'constitute financial advice or an '\n",
              "                                   'endorsement of ANIX or its strategies. '\n",
              "                                   'Disclaimer: FOR EDUCATIONAL AND '\n",
              "                                   'INFORMATION PURPOSES ONLY; NOT INVESTMENT '\n",
              "                                   'ADVICE. Please ensure to fully read and '\n",
              "                                   'comprehend our disclaimer found at '\n",
              "                                   'https://investorbrandmedia.com/disclaimer/. '\n",
              "                                   'InvestorBrandMedia.com has been '\n",
              "                                   'compensated five hundred dollars by a 3rd '\n",
              "                                   'party Bullzeyemedia LLC for advertisement '\n",
              "                                   'and content distribution services on ANIX '\n",
              "                                   'for March 19, 2024. We own zero shares of '\n",
              "                                   'ANIX. InvestorBrandMedia.com is neither an '\n",
              "                                   'investment advisor nor a registered '\n",
              "                                   'broker. No current owner, employee, or '\n",
              "                                   'independent contractor of '\n",
              "                                   'InvestorBrandMedia.com is registered as a '\n",
              "                                   'securities broker-dealer, broker, '\n",
              "                                   'investment advisor, or IA representative '\n",
              "                                   'with the U.S. Securities and Exchange '\n",
              "                                   'Commission, any state securities '\n",
              "                                   'regulatory authority, or any '\n",
              "                                   'self-regulatory organization. This article '\n",
              "                                   'may contain forward-looking statements as '\n",
              "                                   'defined under Section 27A of the '\n",
              "                                   'Securities Act of 1933 and 21E of the '\n",
              "                                   'Exchange Act of 1934. These statements, '\n",
              "                                   'often incorporating terms like “believes,” '\n",
              "                                   '“anticipates,” “estimates,” “expects,” '\n",
              "                                   '“projects,” “intends,” or similar '\n",
              "                                   'expressions about future performance or '\n",
              "                                   'conduct, are based on present '\n",
              "                                   'expectations, estimates, and projections, '\n",
              "                                   'and are not historical facts. They carry '\n",
              "                                   'various risks and uncertainties that may '\n",
              "                                   'result in significant deviation from the '\n",
              "                                   'anticipated results or events. Past '\n",
              "                                   'performance does not guarantee future '\n",
              "                                   'results.InvestorBrandMedia.com does not '\n",
              "                                   'commit to updating forward-looking '\n",
              "                                   'statements based on new information or '\n",
              "                                   'future events. Readers are encouraged to '\n",
              "                                   'review all public SEC filings made by the '\n",
              "                                   'profiled companies at '\n",
              "                                   'https://www.sec.gov/edgar/searchedgar/companysearch. '\n",
              "                                   'It is always important to conduct thorough '\n",
              "                                   'due diligence and exercise caution in '\n",
              "                                   'trading.InvestorBrandMedia.com is not '\n",
              "                                   'managed by a licensed broker, a dealer, or '\n",
              "                                   'a registered investment adviser. The '\n",
              "                                   'content here is purely informational and '\n",
              "                                   'should not be taken as investment advice. '\n",
              "                                   'The Private Securities Litigation Reform '\n",
              "                                   'Act of 1995 provides investors a safe '\n",
              "                                   'harbor regarding forward-looking '\n",
              "                                   'statements. Any statement that projects, '\n",
              "                                   'foresees, expects, anticipates, estimates, '\n",
              "                                   'believes, or understands certain actions '\n",
              "                                   'to possibly occur are not historical facts '\n",
              "                                   'and may be forward-looking statements. '\n",
              "                                   'These statements are based on '\n",
              "                                   'expectations, estimates, and projections '\n",
              "                                   'that could cause actual results to differ '\n",
              "                                   'greatly from those anticipated. Investing '\n",
              "                                   'in micro-cap and growth securities is '\n",
              "                                   'speculative and entails a high degree of '\n",
              "                                   'risk, potentially leading to a total or '\n",
              "                                   'substantial loss of investment. Please '\n",
              "                                   'note that no content published here '\n",
              "                                   'constitutes a recommendation to buy or '\n",
              "                                   'sell a security. It is solely '\n",
              "                                   'informational, and you should not construe '\n",
              "                                   'it as legal, tax, investment, financial, '\n",
              "                                   'or other advice. No content in this '\n",
              "                                   'article constitutes an offer or '\n",
              "                                   'solicitation by InvestorBrandMedia.com or '\n",
              "                                   'any third-party service provider to buy or '\n",
              "                                   'sell securities or other financial '\n",
              "                                   'instruments. The content in this article '\n",
              "                                   'does not address the circumstances of any '\n",
              "                                   'specific individual or entity and does not '\n",
              "                                   'constitute professional and/or financial '\n",
              "                                   'advice. InvestorBrandMedia.com is not a '\n",
              "                                   'fiduciary by virtue of any person’s use of '\n",
              "                                   'or access to this content.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Sources:\\n'\n",
              "                                   '\\n'\n",
              "                                   \"https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023#:~:text=AbbVie%20and%20ImmunoGen,-By%20Eric%20Sagonowsky&text=In%20November%2C%20the%20Illinios%2Dbased,that's%20resistant%20to%20platinum%20chemotherapy.\\n\"\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/quote/ANIX/insider-transactions/\\n'\n",
              "                                   '\\n'\n",
              "                                   'https://finance.yahoo.com/quote/ANIX/\\n'\n",
              "                                   '\\n'\n",
              "                                   'Media Contact\\n'\n",
              "                                   '\\n'\n",
              "                                   'Company Name: Investor Brand Media\\n'\n",
              "                                   '\\n'\n",
              "                                   'Contact Person: Ash K\\n'\n",
              "                                   '\\n'\n",
              "                                   'Email: investorbrandmedia@gmail.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'Phone: (954) 593-5597\\n'\n",
              "                                   '\\n'\n",
              "                                   'Country: United States\\n'\n",
              "                                   '\\n'\n",
              "                                   'Website: https://investorbrandmedia.com/\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   '\\n'\n",
              "                                   'Press Release Distributed by '\n",
              "                                   'ABNewswire.com\\n'\n",
              "                                   '\\n'\n",
              "                                   'To view the original version on ABNewswire '\n",
              "                                   'visit: Anixa Biosciences ANIX Gains '\n",
              "                                   'Attention for Its Innovative Cancer '\n",
              "                                   'Therapies Amid Biopharma Sector Growth'},\n",
              "              'score': 0.733224154,\n",
              "              'values': []},\n",
              "             {'id': '915',\n",
              "              'metadata': {'text': 'UB startup Abceutics Inc. acquired by '\n",
              "                                   'Merck\\n'\n",
              "                                   '\\n'\n",
              "                                   'Abceutics was founded by UB faculty member '\n",
              "                                   'Joseph P. Balthasar and colleagues in '\n",
              "                                   '2020. It is improving the safety and '\n",
              "                                   'efficacy of an important emerging class of '\n",
              "                                   'cancer drugs. Photo: Douglas Levere\\n'\n",
              "                                   '\\n'\n",
              "                                   '“The Abceutics team has already made '\n",
              "                                   'remarkable progress in translating this '\n",
              "                                   'novel idea into reality with a series of '\n",
              "                                   'candidates and compelling early evidence. '\n",
              "                                   'We look forward to further evaluating the '\n",
              "                                   'potential of this innovative approach in '\n",
              "                                   'the clinic. ”\\n'\n",
              "                                   '\\n'\n",
              "                                   'Abceutics Inc., a startup '\n",
              "                                   'preclinical-stage biopharmaceutical '\n",
              "                                   'company that was spun out of the '\n",
              "                                   'laboratory of UB researcher Joseph P. '\n",
              "                                   'Balthasar, has been acquired by the global '\n",
              "                                   'biopharmaceutical company Merck, known as '\n",
              "                                   'MSD outside the U.S. and Canada.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Merck acquired Abceutics for a potential '\n",
              "                                   'consideration of up to $208 million, '\n",
              "                                   'including contingent milestone payments '\n",
              "                                   'based upon the progress of candidates '\n",
              "                                   'under the agreement.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Balthasar, the David and Jane Chu Endowed '\n",
              "                                   'Chair in Drug Discovery and Development in '\n",
              "                                   'the Department of Pharmaceutical Sciences, '\n",
              "                                   'launched the startup in 2020.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The company’s core technology was licensed '\n",
              "                                   'from UB. The technology has been developed '\n",
              "                                   'through grants from the National '\n",
              "                                   'Institutes of Health, as well as $110,000 '\n",
              "                                   'from the Buffalo Innovation Accelerator '\n",
              "                                   'Fund, which is operated by UB’s Business '\n",
              "                                   'and Entrepreneur Partnerships office.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Abceutics has operated out of incubator '\n",
              "                                   'space in UB’s New York State Center of '\n",
              "                                   'Excellence in Bioinformatics and Life '\n",
              "                                   'Sciences, which also provided the company '\n",
              "                                   '$50,000 from Empire State Development’s '\n",
              "                                   'Division of Science, Technology and '\n",
              "                                   'Innovation. Additionally, the company has '\n",
              "                                   'benefitted from the National Science '\n",
              "                                   'Foundation’s Innovation Corps program at '\n",
              "                                   'UB.\\n'\n",
              "                                   '\\n'\n",
              "                                   'Co-founders included Brandon Bordeau and '\n",
              "                                   'Toan Duc Nguyen, former students of the '\n",
              "                                   'Balthasar lab, and Larry Wienkers, a '\n",
              "                                   'pharmaceutical consultant who previously '\n",
              "                                   'served as vice president and global head '\n",
              "                                   'of pharmacokinetics and drug metabolism at '\n",
              "                                   'Amgen Inc. Bordeau, who is now an '\n",
              "                                   'assistant professor at the University of '\n",
              "                                   'Michigan, served as the startup’s chief '\n",
              "                                   'executive officer.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The work of Abceutics is synergistic with '\n",
              "                                   'an important emerging class of medicines '\n",
              "                                   'called antibody-drug conjugates (ADCs). '\n",
              "                                   'ADCs consist of a monoclonal antibody '\n",
              "                                   'coupled to a cytotoxic payload via a '\n",
              "                                   'linker. The antibody component of an '\n",
              "                                   'anticancer ADC specifically targets the '\n",
              "                                   'medicine to particular cancer cells, and '\n",
              "                                   'the cytotoxic payload uses highly potent '\n",
              "                                   'cell-killing properties to then kill the '\n",
              "                                   'targeted cancer cells.\\n'\n",
              "                                   '\\n'\n",
              "                                   'The team engineered “payload-binding '\n",
              "                                   'selectivity enhancers” (PBSEs) to bind and '\n",
              "                                   'neutralize stray payload molecules, '\n",
              "                                   'reducing the impact of these agents on '\n",
              "                                   'otherwise healthy cells.\\n'\n",
              "                                   '\\n'\n",
              "                                   '“PBSEs are intended to be administered '\n",
              "                                   'along with ADCs to reduce the risk of side '\n",
              "                                   'effects, thereby potentially optimizing '\n",
              "                                   'the therapeutic selectively and efficacy '\n",
              "                                   'of ADC therapy,” Balthasar explains.\\n'\n",
              "                                   '\\n'\n",
              "                                   'David Weinstock, vice president of '\n",
              "                                   'oncology discovery in Merck Research '\n",
              "                                   'Laboratories, highlights Abceutics’ '\n",
              "                                   'success.\\n'\n",
              "                                   '\\n'\n",
              "                                   '“The Abceutics team has already made '\n",
              "                                   'remarkable progress in translating this '\n",
              "                                   'novel idea into reality with a series of '\n",
              "                                   'candidates and compelling early evidence,” '\n",
              "                                   'he says. “We look forward to further '\n",
              "                                   'evaluating the potential of this '\n",
              "                                   'innovative approach in the clinic.”\\n'\n",
              "                                   '\\n'\n",
              "                                   'Bordeau says the team is excited for '\n",
              "                                   'Merck, based in Rahway, N.J., to continue '\n",
              "                                   'to explore and develop the PBSE '\n",
              "                                   'technology.\\n'\n",
              "                                   '\\n'\n",
              "                                   '“Merck is recognized as a leader in cancer '\n",
              "                                   'research and has the expertise and '\n",
              "                                   'capabilities needed to bring our PBSE '\n",
              "                                   'technology to patients,” Bordeau says. “We '\n",
              "                                   'are proud to have advanced PBSEs to this '\n",
              "                                   'stage of development and believe that '\n",
              "                                   'Merck is well-suited to build upon the '\n",
              "                                   'progress our company has made.”'},\n",
              "              'score': 0.724842191,\n",
              "              'values': []}],\n",
              " 'namespace': 'ns1',\n",
              " 'usage': {'read_units': 6}}"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# q = []\n",
        "# for i in range(10):\n",
        "#   q.append(r[0].matches[i].metadata['text'])\n",
        "#q[8]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 200
        },
        "id": "_5zxgrbWpVX1",
        "outputId": "92588a3f-ca13-4011-e911-0ea2c52dadb0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Loading... Loading...\\n\\n\\n\\n\"Biotech Stocks In Focus\"\\n\\nDr. Kumar will discuss Anixa\\'s portfolio of first-in-class oncology/immunology assets under development, with vaccines to prevent cancer and a CAR-T cell therapy to treat cancer. The Company\\'s robust pipeline over the next 12 months includes three candidates based on two modalities, three indications, and two ongoing clinical trials.\\n\\n2023 witnessed a remarkable flurry of activity in the biopharmaceutical industry, with several high-profile acquisitions underscoring the sector\\'s dynamic nature and its relentless pursuit of innovation. Here’s a look at some of the most significant deals that not only made headlines but are set to reshape the therapeutic landscape.\\n\\nBefore we get into the recent M and A’s, one biotech company that we would like to draw your attention to is Anixa Biosciences ANIX. Shares of Anixa Biosciences ANIX are up over 15% in the last 5 days.\\n\\nAmid the wave of acquisitions sweeping through the biopharmaceutical sector, could Anixa Biosciences ANIX emerge as a potential compelling contender for buyout consideration?. As a clinical-stage biotechnology company, Anixa is at the forefront of cancer treatment and prevention, wielding a portfolio that could attract interest from larger pharmaceutical firms looking to diversify and enrich their oncology and immunotherapy offerings.\\n\\nAnixa’s Anixa Biosciences ANIX pioneering work includes a collaboration with Moffitt Cancer Center on an ovarian cancer immunotherapy program that leverages cutting-edge chimeric endocrine receptor T-cell (CER-T) technology. This innovation represents a novel approach within the CAR-T therapeutic space, potentially offering a new avenue for treating a variety of cancers. Furthermore, Anixa’s vaccine development efforts, including a groundbreaking vaccine against triple negative breast cancer (TNBC) in collaboration with Cleveland Clinic, positions the company as a leader in prophylactic treatments for some of the most challenging forms of cancer. The vaccine’s focus on “retired” proteins, expressed in certain cancers, exemplifies Anixa’s commitment to novel and potentially transformative therapeutic strategies.\\n\\nAnixa’s business model, characterized by strategic partnerships with renowned research institutions for the clinical development of emerging technologies, enhances its attractiveness as a buyout candidate. This collaborative approach not only accelerates the pace of innovation but also mitigates some of the risks typically associated with drug development by pooling expertise and resources.\\n\\nIn a notable display of confidence in Anixa Biosciences’ potential and direction, two key insiders made significant purchases of the company\\'s stock on March 15, 2024, signaling strong belief in the future of their innovative cancer therapies. Amit Kumar, the Chief Executive Officer of Anixa Biosciences, invested directly in the company by purchasing 30,000 shares at a price of $3.22 per share, totaling an investment of $96,600. Similarly, Arnold M. Baskies, a director of the company, demonstrated his commitment and optimism by acquiring 10,000 shares directly at a price of $3.63 per share, amounting to an investment of $36,300. These transactions underscore the leadership\\'s confidence in Anixa Biosciences\\' strategic initiatives and its continued growth within the biopharmaceutical sector, especially at a time when the company is making significant strides in the development of breakthrough cancer therapies.\\n\\nGiven the current climate of robust M&A activity in the biopharmaceutical industry, driven by a quest for innovative cancer treatments and preventive therapies, Anixa Biosciences potentially stands out as a prime candidate for acquisition. The company’s unique combination of advanced therapeutic and vaccine technologies, along with its strategic alliances, makes it an attractive target for larger entities seeking to bolster their pipelines with promising, high-impact oncology solutions.\\n\\nAt the forefront of 2023\\'s M&A activity, Pfizer\\'s PFE monumental $43 billion merger with Seagen stood out, catalyzing widespread interest in the burgeoning field of antibody-drug conjugates (ADCs). This strategic move is part of Pfizer’s broader diversification strategy, especially at a time when its financial performance was under pressure due to dwindling demand for COVID-19 products. Pfizer\\'s acquisition of Seagen not only enhances its oncology portfolio with four commercial cancer products, including the high-potential bladder cancer treatment Padcev, but also sets the stage for accelerated development of Seagen\\'s robust pipeline through Pfizer\\'s R&D, commercialization, and manufacturing prowess.\\n\\nAbbVie’s ABBV proposed acquisition of ImmunoGen for $10.1 billion is another testament to the industry\\'s intensified focus on ADCs. This deal positions AbbVie within the solid tumor space, capitalizing on ImmunoGen’s expertise and its approved drug Elahere for advanced ovarian cancer. ImmunoGen brings to AbbVie a deep well of ADC knowledge and a pipeline poised for further breakthroughs.\\n\\nIn a deal valued at $14 billion, Bristol Myers Squibb’s BMY acquisition of Karuna Therapeutics underscores its commitment to pioneering neuroscience. Karuna\\'s lead asset, KarXT, a novel treatment for schizophrenia, has the potential to revolutionize the treatment landscape with its unique mechanism and broader therapeutic applications, including Alzheimer’s disease psychosis. This acquisition significantly bolsters BMS\\'s neuropsychiatry pipeline and sets a new course in mental health treatment.\\n\\nMerck\\'s MRK acquisition of Prometheus Biosciences for $10.8 billion marked a significant expansion of its immunology footprint. The deal centered around Prometheus\\'s promising TL1A inhibitor, PRA-023, for ulcerative colitis and Crohn\\'s disease, showcasing the drug\\'s potential to lead in a competitive space. This acquisition not only diversifies Merck’s portfolio but also reinforces its commitment to addressing unmet medical needs in immunology.\\n\\nAbbVie’s ABBV purchase of Cerevel Therapeutics for $8.7 billion late in the year signals a strong belief in the resurgence of neuroscience. Cerevel brings a rich pipeline of potential blockbuster neurotherapeutics, including emraclidine for schizophrenia and Alzheimer’s disease psychosis. This deal is set to significantly enhance AbbVie’s presence in the neurological disorders market.\\n\\nBiogen’s BIIB acquisition of Reata Pharmaceuticals for $7.3 billion focuses on Skyclarys, the first FDA-approved treatment for Friedreich’s ataxia. This deal reflects Biogen’s strategy to lead in the treatment of rare neurological disorders, further solidifying its portfolio of innovative neurological therapies.\\n\\nThese transactions highlight the biopharmaceutical industry\\'s strategic focus on innovation, diversification, and specialization. As these companies integrate their new acquisitions, the healthcare landscape anticipates groundbreaking advancements in treatment options and patient care. The year 2023 has set a remarkable precedent for the future of biopharma M&A, underscoring the industry\\'s resilience and its commitment to advancing human health.\\n\\nLoading... Loading...\\n\\nIn summary, Anixa Biosciences, with its innovative approach to cancer immunotherapy and preventive vaccines, is potentially, uniquely positioned at the intersection of pioneering research and clinical application. The company\\'s strategic collaborations and focus on groundbreaking technologies like CER-T and vaccines targeting TNBC and ovarian cancer make it a standout candidate for acquisition in the rapidly evolving biopharmaceutical landscape. As the industry continues to seek out novel solutions for cancer treatment and prevention, Anixa\\'s Anixa Biosciences ANIX trajectory suggests it could potentially play a pivotal role in shaping the future of oncology.\\n\\nDisclaimer: This article is for informational purposes only and does not constitute financial advice or an endorsement of ANIX or its strategies. Disclaimer: FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated five hundred dollars by a 3rd party Bullzeyemedia LLC for advertisement and content distribution services on ANIX for March 19, 2024. We own zero shares of ANIX. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.\\n\\nSources:\\n\\nhttps://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023#:~:text=AbbVie%20and%20ImmunoGen,-By%20Eric%20Sagonowsky&text=In%20November%2C%20the%20Illinios%2Dbased,that\\'s%20resistant%20to%20platinum%20chemotherapy.\\n\\nhttps://finance.yahoo.com/quote/ANIX/insider-transactions/\\n\\nhttps://finance.yahoo.com/quote/ANIX/\\n\\nMedia Contact\\n\\nCompany Name: Investor Brand Media\\n\\nContact Person: Ash K\\n\\nEmail: investorbrandmedia@gmail.com\\n\\nPhone: (954) 593-5597\\n\\nCountry: United States\\n\\nWebsite: https://investorbrandmedia.com/\\n\\n\\n\\nPress Release Distributed by ABNewswire.com\\n\\nTo view the original version on ABNewswire visit: Anixa Biosciences ANIX Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 478
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# ls = []\n",
        "for j in range(1233,1234):\n",
        "  q = []\n",
        "  for i in range(10):\n",
        "    q.append(r[j].matches[i].metadata['text'])\n",
        "  reranking = vo.rerank(doc_q[j], q, model=\"rerank-lite-1\", top_k=1)\n",
        "  doc = reranking.results[0].document\n",
        ""
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 219
        },
        "id": "UFtHoHZeEr_d",
        "outputId": "3e57efab-bb8f-4664-ae76-ff60a4748234"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "error",
          "ename": "IndexError",
          "evalue": "list index out of range",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mIndexError\u001b[0m                                Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-583-0d8d2d0e702f>\u001b[0m in \u001b[0;36m<cell line: 2>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      3\u001b[0m   \u001b[0mq\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m   \u001b[0;32mfor\u001b[0m \u001b[0mi\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m10\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 5\u001b[0;31m     \u001b[0mq\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mr\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mj\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmatches\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmetadata\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'text'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      6\u001b[0m   \u001b[0mreranking\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mvo\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrerank\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc_q\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mj\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mq\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmodel\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"rerank-lite-1\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtop_k\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      7\u001b[0m   \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mreranking\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mresults\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdocument\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mIndexError\u001b[0m: list index out of range"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "q = []\n",
        "for j in range(len(r)):\n",
        "\n",
        "  for i in range(10):\n",
        "    q.append(r[j].matches[i].metadata['text'])\n",
        ""
      ],
      "metadata": {
        "id": "oy8IDYLkHuF1"
      },
      "execution_count": 42,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "nxuMhvmSAbCq"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "ls = []"
      ],
      "metadata": {
        "id": "FWD993WGtWD-"
      },
      "execution_count": 57,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import time"
      ],
      "metadata": {
        "id": "kanQJBwZBLYN"
      },
      "execution_count": 46,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(r)):\n",
        "    try:\n",
        "      reranking = vo.rerank(doc_q[i] ,q[i*10 :(i + 1) *10], model=\"rerank-lite-1\", top_k=1)\n",
        "      doc = reranking.results[0].document\n",
        "\n",
        "  # Use a generator expression for efficient matching\n",
        "      # matching_id = next((match['id'] for match in r[i]['matches']\n",
        "      #                                 if match['metadata']['text'].strip() == doc), None)\n",
        "\n",
        "      # ls.append(matching_id)\n",
        "      for match in r[i]['matches']:\n",
        "        if match['metadata']['text'].strip() == doc:\n",
        "          ls.append(match['id'])\n",
        "\n",
        "    except Exception as e:\n",
        "      print(f\"Rate limit hit at i={i}. Waiting and retrying...\")\n",
        "      time.sleep(60)  # Wait for 60 seconds before retrying\n",
        "      # i -= 1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "dfSQ1F-pb4RF",
        "outputId": "3a9a0576-2665-4ad5-a0b5-8d93849ce641"
      },
      "execution_count": 62,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Rate limit hit at i=100. Waiting and retrying...\n",
            "Rate limit hit at i=201. Waiting and retrying...\n",
            "Rate limit hit at i=302. Waiting and retrying...\n",
            "Rate limit hit at i=403. Waiting and retrying...\n",
            "Rate limit hit at i=504. Waiting and retrying...\n",
            "Rate limit hit at i=605. Waiting and retrying...\n",
            "Rate limit hit at i=706. Waiting and retrying...\n",
            "Rate limit hit at i=807. Waiting and retrying...\n",
            "Rate limit hit at i=908. Waiting and retrying...\n",
            "Rate limit hit at i=1009. Waiting and retrying...\n",
            "Rate limit hit at i=1110. Waiting and retrying...\n",
            "Rate limit hit at i=1211. Waiting and retrying...\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "(ls)[:25]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "EZ7aH1bABnwQ",
        "outputId": "9c8a5eb9-2414-4d56-9ab1-407f09db4a22"
      },
      "execution_count": 61,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['1112',\n",
              " '1047',\n",
              " '363',\n",
              " '731',\n",
              " '328',\n",
              " '1221',\n",
              " '302',\n",
              " '882',\n",
              " '843',\n",
              " '1107',\n",
              " '856',\n",
              " '755',\n",
              " '497',\n",
              " '213',\n",
              " '1013',\n",
              " '248',\n",
              " '115',\n",
              " '95',\n",
              " '975',\n",
              " '982',\n",
              " '169',\n",
              " '929',\n",
              " None,\n",
              " '1086',\n",
              " '433']"
            ]
          },
          "metadata": {},
          "execution_count": 61
        }
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyNuJYiCdCCrsfvQw4L8CliB",
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}